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Summary 
People who have become dependent on opioid drugs (such as heroin, morphine or codeine) 
may receive a replacement oral pharmacotherapy drug (such as methadone or 
buprenorphine) as part of their treatment. 
Almost 47,000 Australians received pharmacotherapy treatment for their opioid 
dependence on a snapshot day in June 2012. 
The number of people receiving opioid pharmacotherapy treatment has almost doubled 
since 1998 (from around 25,000 people), but growth in client numbers has slowed in recent 
years (to less than 1% a year from 2010 to 2012). 
Methadone continues to be the drug most commonly prescribed; however, the form in 
which buprenorphine is prescribed is changing. 
Around two-thirds (68%) of clients received methadone in 2012, with the proportion 
remaining relatively stable since 2006. The remaining third (32%) received one of two forms 
of buprenorphine. Of these, the proportion receiving buprenorphine only has fallen (from 
23% to 13%) while the proportion receiving buprenorphine combined with naloxone has 
risen (from 6% to 19%) over the same period. Naloxone is added to buprenorphine to deter 
injection of the medication. 
Opioid pharmacotherapy clients are getting older. 
In 2012, around two-thirds (69%) of clients were aged 30 to 49, and this proportion has been 
fairly consistent since 2006. However, from 2006 to 2012 the proportion of clients aged less 
than 30 halved (from 28% to 13%), and the proportion of clients aged 50 and over doubled 
(from 8% to 18%). This suggests an ageing population of clients in pharmacotherapy 
treatment. 
Males and Indigenous people are over-represented in pharmacotherapy treatment. 
Around two-thirds (65%) of clients receiving pharmacotherapy in June 2012 were male. 
Where reported, almost 1 in 10 (9%) clients identified as Indigenous. Indigenous people were 
almost 3 times as likely to have received pharmacotherapy treatment as the population as a 
whole. 
Prescriber numbers have increased, and most work in the private sector. 
There were 1,768 prescribers of opioid pharmacotherapy in Australia in 2012, an increase of 
14% from 2011. On average, each prescriber treated fewer clients, with the ratio of clients per 
prescriber falling from 30 in 2011 to 26 in 2012. The majority of prescribers worked in the 
private sector (82%) and were authorised to prescribe more than one type of 
pharmacotherapy drug (70%).  
Most dosing points were located in pharmacies and in urban areas. 
Most clients need to attend a dosing point regularly to take their opioid pharmacotherapy 
drug under supervision. In 2011–12 there were 2,226 dosing point sites in Australia, and 9 in 
10 (88%) were located in pharmacies. The majority of dosing points were located in Major 
cities (60%) and Inner regional areas (24%), with only 1 in 50 (2%) located in Remote or Very 
remote areas. 
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1 Introduction 
Dependence on opioid drugs such as heroin or morphine is associated with a range of health 
and social problems that affect not only the individual drug user but also their family and 
the community. Opioid dependence is considered a serious public health issue (Box 1.1; 
WHO 2013). In 2010, about 3% of Australians had used opioids for non-medical reasons 
(AIHW 2011). Among those Australians seeking treatment for drug and alcohol problems in 
2010–11, opioids were the primary drug of concern in about 1 in 7 (14%) treatment episodes 
(AIHW 2012). 
Box 1.1: What is drug dependence? 
Drug dependence is a condition characterised by patterns of thought and behaviour that 
relate to drug seeking and using, and may be expressed differently from person to person. 
The Diagnostic and statistical manual of mental disorders (APA 2000) requires that for a 
diagnosis of drug dependence a person must have had at least 3 of the following in a 12-
month period: 
• tolerance, defined by either the need for more of the drug to achieve the same effect, or 
a diminished effect when using the same amount of the drug 
• withdrawal, defined by either the characteristic withdrawal symptoms for the 
particular drug, or the use of the same or closely related drugs, to reduce or avoid 
withdrawal symptoms 
• the drug is taken in larger amounts or over a longer period than intended 
• a persistent desire to stop or unsuccessful attempts to stop using the drug 
• a large amount of time is spent getting, using or recovering from the drug 
• important social, occupational or recreational activities are given up or reduced 
because of drug use 
• the drug is still used even though it is known to cause or exacerbate a physical or 
mental problem. 
What are opioid drugs? 
Opioid drugs have a morphine-type action in the body and depress the central nervous 
system. They are widely used to treat pain due to their analgesic effect. Other effects include 
sedation and euphoria, and repeated use of opioids can lead to drug dependence (NSW 
Health 2006). 
People may become dependent on one or more opioid drugs, including: 
• illicit opioids, predominantly heroin (WHO 2013) 
• prescription opioids (whether prescribed for the person or obtained illicitly) such as 
morphine and oxycodone (Roxburgh et al. 2011) 
• over-the-counter opioids in which the opioid drug codeine is combined with a non-
opioid analgesic such as paracetamol or ibuprofen (Nielsen et al. 2010). 
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What problems can opioid dependence cause? 
Problems associated with heroin dependence include: 
• overdose deaths 
• the spread of diseases such as HIV and Hepatitis B and C due to needle sharing 
• medical and psychological complications 
• social and family disruption 
• harm to the welfare of children 
• violence and drug-related crime (NSW Health 2006). 
Overdose, injection-related harms and harms due to dependence are also related to the non-
medical use of prescription opioids (Roxburgh et al. 2011). Dependence on over-the-counter 
opioids can also lead to life-threatening paracetamol or ibuprofen overdose due to the large 
number of tablets taken to achieve the required codeine dose (Nielsen et al. 2010). 
What treatment is available? 
Opioid dependence is a chronic, relapsing condition that requires long-term treatment. 
Treatment is tailored to the person’s individual circumstances, and treatment types may be 
combined (for example, opioid pharmacotherapy combined with counselling) or varied over 
time (NDARC 2004). The 3 main treatment approaches for opioid dependence are: 
• detoxification (also called withdrawal) 
• opioid pharmacotherapy (also called substitution or maintenance treatment) 
• abstinence-based treatments: 
– self-help groups 
– counselling 
– therapeutic communities (NDARC 2004). 
The broad goal of treatment for opioid dependence is to reduce the health, social and 
economic harms to individuals and the community arising from dependence (DoHA 2007). 
Pharmacotherapy treatment 
Opioid pharmacotherapy involves replacing the drug of dependence with a legally obtained, 
longer-lasting opioid that is taken orally. It reduces or eliminates withdrawal symptoms and 
drug cravings (NDARC 2004). Research suggests that pharmacotherapy treatment reduces 
heroin use and associated criminal behaviour and improves physical and mental health and 
social functioning (Ritter & Chalmers 2009). 
In Australia, 3 medications are registered for short-term detoxification and long-term 
maintenance treatment for opioid-dependent people: 
• methadone oral liquid (available since 1969) 
• buprenorphine tablet (available since 2000) 
• buprenorphine–naloxone tablet (available since 2005) or film (available since 2011) 
(DoHA 2007; DoHA 2012) 
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Box 1.2: Pharmacotherapy types in the NOPSAD collection 
Methadone (Methadone Syrup®, Biodone Forte®) 
Methadone is a synthetic opioid used to treat heroin and other opioid dependence. It 
reduces opioid withdrawal symptoms, the desire to take opioids and the euphoric effect 
when opioids are used. It is taken orally on a daily basis (DoHA 2007). 
Buprenorphine (Subutex®) 
Buprenorphine acts in a similar way to methadone, but is longer-lasting and may be taken 
daily or every second or third day. Two buprenorphine preparations are registered in 
Australia for the treatment of opioid dependence: a product containing buprenorphine only 
and a combined product containing buprenorphine and naloxone. The buprenorphine–only 
product is available as a tablet containing buprenorphine hydrochloride that is 
administered sublingually (by dissolving under the tongue) (DoHA 2007). 
Buprenorphine–naloxone (Suboxone®) 
The combination buprenorphine–naloxone product is a sublingual tablet or film (as of 
1 September 2011) containing buprenorphine hydrochloride and naloxone hydrochloride 
(DoHA 2012). It is recommended that buprenorphine–naloxone should be prescribed in 
preference to buprenorphine for most clients receiving takeaway doses (DoHA 2007).This is 
because, when taken as intended by dissolving the tablet or film under the tongue, the 
combined product acts as if it was buprenorphine alone. However, if the combined product 
is injected, naloxone blocks the effects of buprenorphine and increases opioid withdrawal 
symptoms. This reduces the risk that those receiving buprenorphine–naloxone as a 
takeaway dose will inject it or sell it to others to inject (Chapleo & Walter 1997; DoHA 2007; 
Dunlop 2007). 
Reporting systems in New South Wales do not distinguish between buprenorphine and 
buprenorphine–naloxone. As such, New South Wales data relating to both these products 
are reported under the category of buprenorphine. 
How is opioid pharmacotherapy provided in 
Australia? 
The current Australian opioid pharmacotherapy system seeks to strike a balance between 
maximising accessibility of treatment and minimising the risks associated with non-
compliance (injecting medication) and diversion (selling or swapping medication) (Ritter & 
Chalmers 2009). Methadone and buprenorphine are Schedule 8 (controlled) drugs, which 
means there are strict regulations associated with their use (Ritter & Chalmers 2009). 
Clients seek or are referred to treatment for their opioid dependence. A health professional 
who is authorised to provide opioid pharmacotherapy (a prescriber) prescribes one of 
methadone, buprenorphine or buprenorphine–naloxone as part of the client’s treatment 
plan. Clients are not usually given a whole course of their medication for use at home. 
Rather, the client attends a dosing point regularly and takes one dose of their prescribed 
medication under the supervision of a pharmacist or other health professional. Some 
takeaway doses may be given to eligible clients. See Box 1.3 for more information. 
The Australian and state and territory governments share responsibility and costs for the 
provision of opioid pharmacotherapy services.  
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As described by Ritter and Chalmers (2009), the Australian Government: 
• sets the national policy for opioid pharmacotherapy (DoHA 2007; new policy due 2013) 
• provides national clinical practice guidelines for methadone and buprenorphine (Henry-
Edwards et al. 2003; Lintzeris et al. 2006) 
• provides methadone and buprenorphine free of charge to the dosing body under the 
Pharmaceutical Benefits Scheme (PBS) 
• funds private-sector prescribing (for example, by general practitioners) through 
Medicare. 
The state and territory governments: 
• administer the delivery of opioid pharmacotherapy 
• set policies and clinical guidelines for their jurisdiction 
• regulate, train and accredit prescribers and dosing points 
• register and monitor clients 
• fund prescribing and dosing in public clinics and prisons 
• subsidise service providers in some instances. 
Further information on the opioid pharmacotherapy system and how it varies between states 
and territories is provided in Chapter 5. 
What information is included in the NOPSAD 
collection? 
Information about specialist drug and alcohol treatment services and their clients is collected 
by jurisdictions and compiled by the Australian Institute of Health and Welfare (AIHW) to 
form the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS 
NMDS). This information is reported separately (AIHW 2012). However, the diversity in 
treatment settings for opioid pharmacotherapy, including correctional facilities and private 
clinics, as well as the role of pharmacists and general practitioners in delivering opioid 
pharmacotherapy, place it out of scope for the AODTS NMDS. Instead, data on clients 
receiving opioid pharmacotherapy treatment are routinely collected by state and territory 
health departments. Until 2005, data were provided each year to the Australian Government 
Department of Health and Ageing (DoHA). 
The National Opioid Pharmacotherapy Statistics Annual Data (NOPSAD) collection 
commenced in 2005 and comprises data about opioid pharmacotherapy clients, prescribers 
and dosing points collected by state and territory health departments and reported to the 
AIHW. Refer to Box 1.3 for further information. While states and territories strive to report 
data consistent with agreed standards, the NOPSAD collection is not a national minimum 
data set and some discrepancies exist in the ways in which data are reported. These 
discrepancies are discussed in more detail in Table 5.1 and Table 5.2. 
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Box 1.3: Definitions 
Several terms are used throughout this publication that are specific to this report and 
subject matter. Full definitions are in the National Opioid Pharmacotherapy Statistics Annual 
Data (NOPSAD) 2012 collection data guide (AIHW 2012a). This data guide is made available 
each year to complement the NOPSAD report and provide a clearer understanding about 
what is and what is not being reported. 
Specified/snapshot day or snapshot day is a particular day, usually in June each year, on 
which clients are counted for the NOPSAD collection. This allows the number of clients to 
be estimated at a single point in time. The snapshot day varies between states and 
territories. See Table 5.1 for information about the use of the snapshot day for each state and 
territory. 
Client refers to a person registered as receiving opioid pharmacotherapy treatment on the 
snapshot day. 
Prescriber refers to a registered prescriber who is accredited and/or authorised to prescribe 
a pharmacotherapy drug and who has not been recorded as ceasing this registration before 
the snapshot day. More specifically, prescribers are included in the count if they are 
registered or authorised prescribers, or active prescribers, that is, prescribers who are 
scripting at least one client during the reporting period (that is, each financial year). 
Prescriber type is defined as the sector (public or private) in which the prescriber is 
practising when prescribing pharmacotherapy drugs. 
Dosing point site refers to a place at which at least one client is provided a 
pharmacotherapy drug on the snapshot day. Sites include public and private clinics (such 
as methadone clinics), pharmacies, correctional facilities, hospitals (inpatients and 
outpatients) and other locations such as community health centres and doctors’ surgeries. 
What is the NOPSAD collection used for? 
The NOPSAD collection is one of a number of data sources that provide a picture of alcohol 
and other drug treatment services in Australia. Data from the collection can be considered 
with information from other sources (for instance, the AODTS NMDS and the National Drug 
Strategy Household Survey) to inform debate, policy decisions and planning processes that 
occur within the broader alcohol and other drug treatment sector. More specifically, 
pharmacotherapy data are used in states and territories to: 
• monitor resources required for pharmacotherapy treatment, such as the number of 
prescribers and dosing point sites 
• monitor and plan services (for example, monitoring prescriber patterns and the number 
of clients) 
• develop and refine policies relating to the treatment of clients with opioid dependency 
• track the number of clients moving between the public and private sectors. 
Data are also used to fill gaps in national treatment services data. See appendices A, B and C 
for more information about the NOPSAD data as well as related data collections. 
The NOPSAD reports are available free online at < www.aihw.gov.au/alcohol-and-other-
drugs/>. 
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2  Clients 
This chapter presents information about people who were clients of opioid pharmacotherapy 
treatment on the snapshot day in June 2012.  
As this chapter shows, clients vary in age, sex and Indigenous status. The example client 
described in Box 2.1 represents the most common demographic and treatment 
characteristics, but does not illustrate the diversity of clients receiving opioid 
pharmacotherapy. It is a hypothetical example and is not based on any one client. 
Box 2.1: An example of an opioid pharmacotherapy client 
Jason tried a lot of drugs as a teenager, but never thought he would become a heroin addict. 
He started using heroin occasionally on weekends, but soon found he had to have it every 
day. After losing his job and his partner due to his habit, he sought treatment. He was 
started on methadone maintenance treatment, and was also given counselling. 
Jason has since learnt that he is a fairly typical opioid pharmacotherapy client: around 40 
years old, male and living in a big city. His treatment is managed by his GP, who has 
completed specialised training so that he can prescribe methadone. Jason visits his local 
pharmacy several times a week to take his methadone under the supervision of the 
pharmacist. Because he has been doing well on the program, he is allowed to have some of 
his methadone doses unsupervised. This means he can take home some of his methadone 
doses and he does not have to go to the pharmacy every day. 
Apart from one relapse, methadone has helped Jason to stop taking heroin. Now that he 
doesn’t have to spend all his time and money trying to get his next ‘fix’, he feels more in 
control of his life, and has recently started working again. 
2.1 How many people receive pharmacotherapy 
treatment? 
On a snapshot day in June 2012, 46,697 clients were receiving pharmacotherapy treatment in 
Australia. Client numbers grew slightly (by less than 1% annually) between 2010 and 2012. 
In contrast, between 1998 and 2004, and again between 2007 and 2010, client numbers grew 
by 5–13% a year (Figure 2.1).  
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Source: Table A1. 
Figure 2.1: Clients receiving pharmacotherapy on a snapshot day, 1998–2012 
Nationally, the number of clients per 10,000 people increased from 13 in 1998 to 21 in 2010, 
and remained at 21 in 2011 and 2012 (Table A2). In 2012, New South Wales (26 clients per 
10,000 population) had the highest rate of clients, followed by Victoria (25), and the 
Australian Capital Territory (24). The Northern Territory had the lowest rate of clients (5 
clients per 10,000 population), followed by Tasmania (12) (Figure 2.2). The low rate of clients 
in the Northern Territory may be partially attributable to the absence of an established 
heroin market in Darwin (Moon 2010), the impact of remote locations on treatment delivery 
and a highly mobile population. Rates for all states and territories were similar to those 
reported in 2011. 
 
Source: Table A2. 
Figure 2.2: Clients receiving pharmacotherapy by state and territory, on a snapshot day in 2012 
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2.2 What drugs do clients receive? 
On a snapshot day in June 2012: 
• 68% of clients received methadone 
• 13% received buprenorphine 
• 19% received buprenorphine–naloxone (Table A3). 
However, it should be noted that New South Wales does not report clients receiving 
buprenorphine–naloxone separately, but rather includes them within the total number of 
clients receiving buprenorphine. If New South Wales data are excluded, in the rest of 
Australia: 
• 62% of clients received methadone 
• 7% received buprenorphine 
• 31% received buprenorphine–naloxone. 
From 2006 to 2012, the national proportion of clients receiving methadone fell slightly from 
71% to 68%. In the same period, the proportion of clients receiving buprenorphine fell from 
23% to 13%, while the proportion receiving buprenorphine–naloxone rose from 6% to 19% 
(Figure 2.3). These data should be interpreted with caution, as separate data collection for 
buprenorphine–naloxone did not start until 2007 or 2008 in some jurisdictions, and has not 
commenced in NSW (see Table 5.2 for more details). Nonetheless, it appears that 
buprenorphine–naloxone prescription is replacing buprenorphine prescription to some 
extent. This is in keeping with the National pharmacotherapy policy for people dependent on 
opioids (DoHA 2007), which recommends that buprenorphine–naloxone should be preferred 
over buprenorphine for most clients receiving takeaway doses.  
 
Notes 
1. Data collection for buprenorphine–naloxone started at different times in the jurisdictions—in 2006 for Vic, WA, SA, NT; in 2007 for Tas and 
the ACT, and 2008 for Qld. 
2. NSW counts buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
Source: Tables A3 and A4. 
Figure 2.3: Clients, by pharmacotherapy type on a snapshot day in Australia, 2006–2012 
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The proportion of clients receiving each of the 3 pharmacotherapies varies across states and 
territories. In 2012, methadone was the most common pharmacotherapy in all jurisdictions 
except for the Northern Territory. The jurisdiction with the highest proportion of clients 
receiving methadone was the Australian Capital Territory (82%), followed by New South 
Wales (76%). In contrast, only 30% of clients in the Northern Territory were prescribed 
methadone. The Northern Territory had the highest proportion of clients receiving 
buprenorphine–naloxone (59%) (Figure 2.4). Buprenorphine–naloxone is the default 
treatment drug for the main pharmacotherapy program in the Northern Territory. 
 
Note: NSW counts buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
Source: Table A3. 
Figure 2.4: Clients, by pharmacotherapy type and state and territory, on a snapshot day, 2012 
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2.3 Who receives pharmacotherapy treatment? 
Sex 
Around two-thirds (65%) of the clients receiving pharmacotherapy in June 2012 were male. 
This proportion was similar for each of the 3 pharmacotherapy types (Figure 2.5) and has 
remained stable since 2006 (Table A5). 
 
Note: NSW counts buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
Source: Table 2.1. 
Figure 2.5: Clients, by sex and pharmacotherapy type, on a snapshot day, 2012 
A similar pattern of around two-thirds male clients was observed at the state and territory 
level, ranging from 58% of clients being male in Tasmania to 66% in New South Wales and 
Victoria (Table 2.1). In Victoria, information on sex is not collected but estimated by the data 
supplier. The data are included to enable analysis, but should be treated with caution.  
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Table 2.1: Number of clients by sex, pharmacotherapy type, and state and territory, 2012 
Sex NSW Vic(a) Qld WA SA Tas ACT NT Aust Aust (%) 
 
Methadone 
Male 9,273 6,195 1,709 1,349 1,173 188 447 26 20,360 64.2 
Female 4,972 3,087 1,292 834 714 132 288 10 11,329 35.7 
Not stated — 48 — — — — — — 48 0.2 
Total 14,245 9,330 3,001 2,183 1,887 320 735 36 31,737 100.0 
 
Buprenorphine(b) 
Male 3,060 388 450 44 151 27 30 6 4,156 65.8 
Female 1,410 193 345 52 104 40 6 8 2,158 34.2 
Not stated — 3 — — — 0 — — 3 0.0 
Total 4,470 584 795 96 255 67 36 14 6,317 100.0 
 
Buprenorphine–naloxone 
Male n.a. 2,737 1,331 628 725 148 75 43 5,687 65.8 
Female n.a. 1,363 692 366 348 91 47 28 2,935 34.0 
Not stated n.a. 21 — — — — — — 21 0.2 
Total n.a. 4,121 2,023 994 1,073 239 122 71 8,643 100.0 
 
Total (all pharmacotherapy drugs) 
Male 12,333 9,320 3,490 2,021 2,049 363 552 75 30,203 64.7 
Female 6,382 4,643 2,329 1,252 1,166 263 341 46 16,422 35.2 
Not stated — 72 — — — — — — 72 0.2 
Total 18,715 14,035 5,819 3,273 3,215 626 893 121 46,697 100.0 
(a) The apparent uniformity of gender breakdown across drug types in Vic is not measured but estimated. 
(b) NSW counts buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
Age 
Since 2006, when information about the age of a client was first collected, the proportion of 
older clients within the treatment population has increased. Around two-thirds (69%) of 
clients in 2012 were aged 30 to 49, and this proportion has been fairly consistent since 2006. 
However, from 2006 to 2012 the proportion of clients aged less than 30 halved (from 28% to 
13%), and the proportion of clients aged 50 and over doubled (from 8% to 18%) (Figure 2.6). 
This trend towards older pharmacotherapy clients has also been observed overseas (see, for 
example, Doukas 2011 and Dürsteler-MacFarland et al. 2011) and may be due to: 
• methadone treatment having been available for more than 40 years 
• pharmacotherapy treatment reducing the risk of premature death, resulting in some 
clients remaining in treatment for decades 
• clients seeking treatment for the first time at an older age 
• the ageing of the population in general, and ‘baby boomers’ in particular (Doukas 2011). 
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Source: Table A6. 
Figure 2.6: Clients, by age group, receiving pharmacotherapy, on a snapshot day, 2006–2012 
In 2012, clients ranged in age from their mid-teens to their late-80s. The median age of clients 
across all pharmacotherapy types was 39 years, compared with 38 years in 2011 (the first 
year in which these data could be reported). Clients receiving methadone had a slightly 
higher median age (40 years) than clients receiving buprenorphine or buprenorphine–
naloxone (38 years and 37 years respectively) (Table 2.2). At a state and territory level, clients 
in Victoria and Tasmania had the youngest median age (37 years) and clients in New South 
Wales and South Australia had the oldest median age (40 years) (Table 2.2). In Victoria, 
information on age is not collected but estimated by the data supplier. The data are included 
to enable analysis, but should be treated with caution.  
Table 2.2: Median age by state and pharmacotherapy type, 2012 
  NSW Vic(a) Qld WA SA Tas ACT NT Aust 
Methadone 41 37 41 39 41 39 38 39 40 
Buprenorphine(b) 38 37 37 34 42 36 40 45 38 
Buprenorphine–
naloxone n.a. 37 37 37 38 35 38 37 37 
Total 40 37 39 38 40 37 38 38 39 
(a) The apparent uniformity of median age across drug types is not measured in Vic but estimated. 
(b)  NSW counts buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
In 2012, methadone was the most commonly dispensed pharmacotherapy across all age 
groups. As age increased, the proportion of clients receiving methadone increased, and the 
proportion receiving buprenorphine or buprenorphine–naloxone decreased (Figure 2.7). As 
buprenorphine was registered in Australia for opioid pharmacotherapy in 2000, and 
buprenorphine–naloxone was only registered in 2005 (DoHA 2007), a possible explanation 
for the observed trend might be that some older, long-term clients first entered treatment 
when methadone was the only available pharmacotherapy for opioid dependence. 
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Source: Table A7. 
Figure 2.7: Clients, by age group and pharmacotherapy type, on a snapshot day, 2012 
Aboriginal and Torres Strait Islander people 
In 2012, 6 states and territories were able to provide information about the Indigenous status 
of clients receiving pharmacotherapy treatment, including Tasmania and the Northern 
Territory who provided these data for the first time. Victoria and Western Australia did not 
report the Indigenous status of their clients, with the result that Indigenous status was only 
reported for around two-thirds (63%) of clients in the collection. Furthermore, Indigenous 
status was not stated for 9% of clients in the 6 reporting states and territories. Jurisdictions 
are working towards improving the quality of Indigenous data for this collection, but the 
analysis of the 2012 data that follows should be treated with caution due to the high 
proportion of clients (43%) for whom Indigenous status is either not reported or not stated. 
Of the 29,389 clients in the 6 jurisdictions reporting Indigenous status in 2012, 2,588 (9%) 
identified as being of Aboriginal and/or Torres Strait Islander origin (Table 2.3). The 
proportion of Indigenous clients ranged from 4% in Tasmania and Queensland to 10% in 
New South Wales and the Australian Capital Territory. 
Overall, for the 6 states and territories reporting Indigenous status, there were 55 Indigenous 
clients per 10,000 Indigenous people. This suggests an over-representation of Indigenous 
people receiving pharmacotherapy treatment when compared with the overall rate of 21 
clients per 10,000 people. Three jurisdictions had relatively high rates of Indigenous clients: 
the Australian Capital Territory (182 clients per 10,000 Indigenous people), New South Wales 
(113) and South Australia (86). The high rate in the Australian Capital Territory should be 
regarded with caution as it has a small Indigenous population. In contrast, Queensland had 
14 Indigenous clients per 10,000 Indigenous people, Tasmania had 10 and the Northern 
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Territory only had 1 Indigenous client per 10,000 Indigenous people. This very low rate in 
the Northern Territory is consistent with the low overall rate of pharmacotherapy (5 clients 
per 10,000 people). 
Three-quarters (74%) of Indigenous clients received methadone, with the remaining quarter 
(26%) receiving either buprenorphine or buprenorphine–naloxone (Table 2.3).  
Table 2.3: Clients, by Indigenous status, pharmacotherapy type, and state and territory, on a 
snapshot day, 2012 
Indigenous status NSW Vic Qld WA SA Tas ACT NT Aust 
Aust  
(per cent) 
 
Methadone 
Indigenous 1,518 n.a. 121 n.a. 165 20 83 n.p. 1,907 9.4 
Non-indigenous 10,867 n.a. 2,411 n.a. 1,722 261 633 33(c) 15,927 78.8 
Not stated 1,860 n.a. 469 n.a. — 39 19 3 2,390 11.8 
Sub-total 14,245 n.a. 3,001 n.a. 1,887 320 735 36 20,224 100.0 
Not reported(a) — 9,330 — 2,183 — — — — 11,513 n.a. 
Total 14,245 9,330 3,001 2,183 1,887 320 735 36 31,737 . . 
 
Buprenorphine(b) 
Indigenous 436 n.a. 35 n.a. 14 — — n.p. 485 8.6 
Non-indigenous 3,879 n.a. 724 n.a. 241 63 34 13(c) 4,954 87.9 
Not stated 155 n.a. 36 n.a. — 4 2 1 198 3.5 
Sub-total 4,470 n.a. 795 n.a. 255 67 36 14 5,637 100.0 
Not reported(a) — 584 — 96 — — — — 680 n.a. 
Total 4,470 584 795 96 255 67 36 14 6,317 . . 
 
Buprenorphine–naloxone 
Indigenous n.a. n.a. 88 n.a. 95 n.p. 7 6 196 5.6 
Non-indigenous n.a. n.a. 1,839 n.a. 978 230(c) 112 65 3,224 91.4 
Not stated n.a. n.a. 96 n.a. — 9 3 — 108 3.1 
Sub-total n.a. n.a. 2,023 n.a. 1,073 239 122 71 3,528 100.0 
Not reported(a) n.a. 4,121 — 994 — — — — 5,115 n.a. 
Total n.a. 4,121 2,023 994 1,073 239 122 71 8,643 . . 
 
Total (all pharmacotherapy drugs) 
Indigenous 1,954 n.a. 244 n.a. 274 20 90 6 2,588 8.8 
Non-indigenous 14,746 n.a. 4,974 n.a. 2,941 554 779 111 24,105 82.0 
Not stated 2,015 n.a. 601 n.a. — 52 24 4 2,696 9.2 
Sub-total 18,715 n.a. 5,819 n.a. 3,215 626 893 121 29,389 100.0 
Not reported(a) — 14,035 — 3,273 — — — — 17,308 n.a. 
Total 18,715 14,035 5,819 3,273 3,215 626 893 121 46,697 . . 
 
Number of Indigenous clients per 10,000 Indigenous people (all pharmacotherapy drugs) 
  113 n.a. 14 n.a. 86 10 182 1 55   
(a) Vic and WA do not report Indigenous status. 
(b) NSW counts buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
(c)  Includes both Indigenous and Non-Indigenous clients. The number of Indigenous clients is small (<3). 
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3 Prescribers 
3.1 How are prescribers authorised? 
Opioid pharmacotherapies are prescribed by medical personnel such as general practitioners 
and medical specialists. Each state and territory has a registration process through which 
prescribers can undergo training and become registered to prescribe opioid 
pharmacotherapies to clients. Some jurisdictions also authorise prescribers to prescribe 
opioid pharmacotherapies for a small number of clients without undergoing the specified 
training. Data on all registered or authorised prescribers are included in this report, except 
for New South Wales, Western Australia and South Australia where prescribers are included 
only if they are actively prescribing for at least 1 client on the snapshot day (see Table 5.2 for 
further details). 
Nationally, there were 1,768 prescribers authorised to prescribe 1 or more pharmacotherapy 
drugs in 2012. This was an increase of 219 prescribers (14%) from 2011. 
Of these 1,768 prescribers: 
• 70% (1,242) were authorised to prescribe more than one pharmacotherapy type. 
• 20% (361) were authorised to prescribe methadone only. 
• 5% (95) were authorised to prescribe buprenorphine–naloxone only.  
• 4% (70) were reported as authorised to prescribe buprenorphine only, but were all 
located in New South Wales, which counts both buprenorphine and buprenorphine–
naloxone under ‘Buprenorphine’ (Figure 3.1). 
The proportion of prescribers authorised to prescribe more than one pharmacotherapy type 
increased from 51% in 2006 to 70% in 2012. The increase in the proportion of prescribers 
authorised to prescribe buprenorphine–naloxone only (from 1% in 2011 to 5% in 2012) 
occurred mainly in South Australia and is probably due to the introduction of the 
Suboxone® Opioid Substitution Program (SOSP) in South Australia, discussed in more detail 
below. 
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Notes 
1. 2011 prescriber numbers have been revised for Vic and as such totals are different from previous publications. 
2. NSW counts buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
Source: Table A8 and Table 3.1. 
Figure 3.1: Prescribers, by pharmacotherapy type, 2006–2012 
All prescribers in the Australian Capital Territory and the Northern Territory were 
registered to prescribe more than one drug type in 2012. Some prescribers in the other 6 
jurisdictions were only registered to prescribe a single drug type (Table 3.1). 
Table 3.1: Prescribers(a), by pharmacotherapy type, and state and territory, 2012  
Pharmacotherapy type NSW(b) Vic  Qld WA SA(b) Tas ACT NT Aust 
Methadone only 223             119             4 7 — 8 — — 361 
Buprenorphine only(c) 70               — — — — — — — 70 
Buprenorphine–naloxone 
only  n.a.  — 2 — 93 — — — 95 
More than one drug type 300             566 126 88 73 25 56 8 1,242 
Total (number) 593 685 132 95 166 33 56 8 1,768 
Total (per cent) 33.5 38.7 7.5 5.4 9.4 1.9 3.2 0.5 100.0 
(a) The states and territories may have different guideline and policies regarding training to prescribe opioid pharmacotherapy types. See Table 
5.3 for more information. 
(b) See Table 5.2 for more information about NSW and SA reporting of registered prescribers. 
(c) NSW counts buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
Between 2011 and 2012, prescriber numbers fell by 18% in Western Australia, 11% in the 
Northern Territory and 6% in Tasmania. Prescriber numbers rose in all other states and 
territories. The largest rise was seen in South Australia, where the total number of 
prescribers almost doubled (from 85 to 166), due to a large increase in the number of 
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buprenorphine–naloxone-only prescribers (from 13 to 93). This is most likely due to the 
introduction of the Suboxone® Opioid Substitution Program (SOSP) in South Australia in 
April 2011, under which any medical practitioner may be authorised to prescribe Suboxone® 
(buprenorphine–naloxone) film for up to 5 patients without having to undertake formal 
accreditation (SA Health 2011).  
3.2 Where do prescribers work? 
Prescribers are classified according to the sector in which they are working when prescribing 
pharmacotherapy drugs to clients. 
• Private prescribers work in organisations that are not controlled by government, such as 
private general practice (GP) clinics. 
• Public prescribers work in organisations that are part of government or are government-
controlled, such as public drug and alcohol clinics and public hospitals. 
• Correctional facility prescribers work in prisons or other correctional services 
Of the 1,768 prescribers authorised to prescribe pharmacotherapy drugs in 2012: 
• 82% (1,451) were private prescribers. 
• 12% (218) were public prescribers. 
• 3% (60) were correctional facility prescribers (Table 3.2). 
In 2012, Victoria had no public prescribers, and so had the highest proportion of private 
prescribers (97%). This was followed by South Australia (89% private prescribers) and the 
Australian Capital Territory (88% private prescribers). The Northern Territory had the 
highest proportion of public prescribers (63%), followed by Tasmania (42%) (Table 3.2). 
Table 3.2: Prescribers(a), by prescriber type, and state and territory, 2012 
Prescriber type NSW Vic  Qld WA SA Tas ACT NT Aust 
Private prescriber 411 667 92 65 148 17 49 2 1,451 
Public prescriber 133 — 30 20 13 14 3 5 218 
Public/private prescriber(b) 29 — — — — — 3 — 32 
Correctional facilities 13 18 10 10 5 2 1 1 60 
Correctional/private(b) 3 — — — — — — — 3 
Correctional/public/private(b) 4 — — — — — — — 4 
Total 593 685 132 95 166 33 56 8 1,768 
(a) See Table 5.2 for more information about NSW and SA reporting of registered prescribers. 
(b) In NSW and the ACT, these figures relate to prescribing that cannot be separated into a single prescriber type. 
The number of each prescriber type among the states and territories has remained relatively 
stable over time, with the exception of South Australia where the number of private 
prescribers more than doubled from 67 in 2011 to 148 in 2012. As previously discussed, this 
is likely to be due to the introduction of the Suboxone® Opioid Substitution Program (SOSP) 
in South Australia in April 2011. More specifically, the majority of South Australian clients 
(3,071) were managed via the Opioid Dependence Substitution Program (ODSP) by 73 
prescribers (methadone, buprenorphine & Suboxone®), and 144 clients were managed via 93 
SOSP prescribers (Suboxone® only).  
 18 National Opioid Pharmacotherapy Statistics Annual Data Collection 2012 
3.3 How many clients do prescribers treat? 
Number of clients by prescriber type 
Of the 46,697 clients receiving treatment on the snapshot day in June 2012: 
• 65% (30,486) received treatment from a private prescriber. 
• 28%(12,881) received treatment from a public prescriber. 
• 7% (3,068) received treatment from a correctional facility prescriber (Figure 3.2). 
These proportions have remained relatively stable since 2006 (Figure 3.2). 
 
Source: Table A10. 
Figure 3.2: Clients, by prescriber type, on a snapshot day, 2005–2012 
Private prescribers treated the majority of clients in New South Wales, Victoria, Western 
Australia and South Australia. Public prescribers treated the majority of clients in 
Queensland, Tasmania, the Australian Capital Territory and the Northern Territory 
(Table 3.3). This pattern is similar to that observed in 2011 for all jurisdictions except 
Tasmania. In Tasmania, the majority of clients were treated by private prescribers in 2011, 
but by public prescribers in 2012. This is probably a reflection of the fact that between 2011 
and 2012 the number of public prescribers in Tasmania rose (by 56%) while the number of 
private prescribers fell (by 29%) (Table 3.2).  
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Table 3.3: Clients, by pharmacotherapy type, prescriber type, and state and territory, 
 on a snapshot day, 2012 
Prescriber type NSW  Vic Qld WA SA Tas ACT NT Aust 
  Methadone 
Private prescriber 8,400 8,522 969 1,059 1,056 224 230 11(c) 20,471 
Public prescriber 4,356 — 2,009 833 656 96 411 25 8,386 
Public/private prescriber(a) 183 — — — — — — — 183 
Correctional facility 1,306 808 23 291 175 — 94 n.p. 2,697 
Total 14,245 9,330 3,001 2,183 1,887 320 735 36 31,737 
  Buprenorphine(b) 
Private prescriber 2,416 584(c) 387 52 149(c) 17(c) 12 n.p. 3,617 
Public prescriber 1,790 — 400 44 106 50 24 14(d) 2,428 
Public/private prescriber(a) 79 — — — — — — — 79 
Correctional facility 185 n.p. 8 — n.p. n.p. — — 193 
Total 4,470 584 795 96 255 67 36 14 6,317 
  Buprenorphine–naloxone 
Private prescriber — 4,063 990 620 639 49(c) 36 5 6,402 
Public prescriber — — 1022 351 354 190 86 66 2,069 
Public/private prescriber(a) — — — — — — — — — 
Correctional facility — 58 11 23 80 n.p. — — 172 
Total — 4,121 2,023 994 1,073 239 122 71 8,643 
  Total (all pharmacotherapy drugs) 
Private prescriber 10,816 13,169 2,346 1,731 1,844 290 278 16 30,490 
Public prescriber 6,146 — 3,431 1,228 1,116 336 521 105 12,883 
Public/private prescriber(a) 262 — — — — — — — 262 
Correctional facility 1,491 866 42 314 255 n.p. 94 n.p. 3,062 
Total 18,715 14,035 5,819 3,273 3,215 626 893 121 46,697 
 
Total (per cent of all pharmacotherapy drugs) 
Private prescriber 57.8 93.8 40.3 52.9 57.4 46.3 31.1 13.2 65.3 
Public prescriber 32.8 — 59.0 37.5 34.7 53.7 58.3 86.8 27.6 
Public/private prescriber(a) 1.4 — — — — — — — 0.6 
Correctional facility 8.0 6.2 0.7 9.6 7.9 n.p. 10.5 n.p. 6.6 
Total (%) 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
(a) In NSW, these figures relate to prescribing that cannot be separated into public or private prescribers. 
(b) NSW counts buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
(c) Refers to the number of clients receiving treatment from a private prescriber and a correctional facility. The number of  
clients by correctional facility prescriber is small (<3). 
(d) Refers to the number of clients receiving treatment from a public prescriber and a private prescriber. The number of  
clients by private prescriber is small (<3). 
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Clients per prescriber 
On the snapshot day in 2012, 1,768 prescribers were treating an average of 26 clients each 
(compared to an average of 30 clients in 2011). The client-per-prescriber ratio fell in 2012 
because the number of clients grew only slightly (by less than 1%) between 2011 and 2012, 
but the number of prescribers grew by 14% in the same period. 
Between 2005 (the first year data were available) and 2012, the number of clients per 
prescriber rose in Queensland (by 9 clients) and Tasmania (by 12 clients), and fell in all other 
states and territories. In 2012, Queensland had the highest number of clients per prescriber 
(44 clients) of any jurisdiction (Figure 3.3). However, this ratio may be overstated in 
Queensland due a possible undercounting of prescribers in public clinics (caused by multiple 
prescribers sharing one prescriber identification number when prescribing for opioid 
pharmacotherapy clients). 
Between 2011 and 2012, the number of clients per prescriber fell in South Australia (from 37 
to 19) and Queensland (from 54 to 44), due to a rise in prescriber numbers in those 2 states. 
The ratio rose in Western Australia (from 29 to 34) due to a fall in prescriber numbers. The 
average number of clients per prescriber remained relatively stable in the other states and 
territories (Figure 3.3). 
 
Note: 2011 prescriber numbers have been revised for Vic and are different from previous publications. This also affects the Australian total. 
Source: Table A11. 
Figure 3.3: Ratio of clients to prescriber, by state and territory, on a snapshot day, 2005–2012 
In 2012, prescribers working in the public sector had, on average, almost 3 times as many 
clients as prescribers working in the private sector (58 clients per prescriber compared with 
21). Public prescribers in the Australian Capital Territory (174 clients) and Queensland (114 
clients) had a particularly high average number of clients. Private prescribers had a lower 
average number of clients than public prescribers in all states and territories except for 
Victoria, which had no public prescribers. 
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Prescribers working in correctional facilities had an average of 46 clients nationally, but at a 
state and territory level this varied widely from 1 client per prescriber in Tasmania to 94 
clients per prescriber in the Australian Capital Territory (Figure 3.4). 
 
Source: Table A12. 
Figure 3.4: Ratio of clients to prescribers, by prescriber type and state and territory, 2012 
3.4 Does drug treatment vary between sectors? 
In 2012, methadone was the most commonly prescribed drug in all sectors. However, 
prescribers in correctional facilities disproportionately prescribed methadone (to 88% of 
clients) when compared with public (65%) or private (67%) prescribers. Private prescribers 
disproportionately prescribed buprenorphine–naloxone (21%) compared with public (16%) 
or correctional facility (6%) prescribers (Figure 3.5). This is a similar pattern to that observed 
in 2011 (Table A9). 
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Note: NSW counts buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
Source: Table A9. 
Figure 3.5: Clients, by pharmacotherapy type and prescriber type, on a snapshot day, 2012 
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4 Dosing points 
4.1 Where are pharmacotherapy drugs provided? 
Number and type of dosing point sites 
A dosing point is the site where clients receive the medication prescribed for them. In 
general, clients attend a dosing point and receive one dose of medication, which they take 
under supervision, in order to reduce the risks of diversion, misuse or overdose. However, 
stable clients may be authorised to take home one or more ‘takeaway’ doses for use on 
subsequent days (DoHA 2007). 
In 2011–12 there were 2,226 dosing points in Australia, an increase of 26 (1%) from 2010–11. 
In the same period the number of dosing points rose in Queensland (by 8%), fell in the 
Northern Territory (by 9%) and Western Australia (by 8%), and remained relatively steady in 
the other states and territories. 
Nationally, the majority of dosing points were pharmacies (88%), followed by hospitals (7%) 
and public clinics (2%) (Table 4.1). These proportions are very similar to those observed in 
2010–11 (Table A13). Pharmacies were also the most common dosing point site in all states 
and territories, with the proportion ranging from 80% in the Northern Territory and 
Queensland to 97% in Western Australia (Table 4.1). 
Table 4.1: Dosing point sites, by state and territory, 2011–12 
Dosing point sites NSW(a) Vic Qld WA SA Tas ACT NT Aust 
Aust 
(per cent) 
Public clinic 36 — 10 1 2 1 1 1 52 2.3 
Private clinic 12 — 8 — — — — — 20 0.9 
Pharmacy 640 436 377 230 188 52 31 8 1,962 88.1 
Correctional setting 1 11 4 2 7 1 1 1 28 1.3 
Hospital 70 11 62 4 1 1 — — 149 6.7 
Other(b) 5 — 9 — 1 — — — 15 0.7 
Total (number) 764 458 470  237 199    55  33 10  2,226  100.0 
Total (per cent)    34.3  20.6  21.1  10.6  8.9   2.5    1.5  0.4   100.0  . . 
(a) See tables 5.1 and 5.2 for more information about NSW. NSW correctional dosing points are reported under a single facility. 
(b) The category ‘Other’ includes mobile dosing sites, community health clinics, non-government organisations, doctors’ surgeries and dosing 
points ‘not stated’. 
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Geographic location 
Clients need to attend dosing sites regularly to collect their medication, so it is important that 
dosing sites are in locations that are readily accessible by clients. For the first time in 2012, 
data on the geographic location of dosing sites have been included in the NOPSAD 
collection. The Australian Standard Geographical Classification (ASGC) classifies areas into 
Major cities, Inner regional areas, Outer regional areas, Remote and Very remote areas. Not all 
remoteness areas are found in each state and territory. 
• In 2011–12, dosing points were mostly located in Major cities (60%) and Inner regional 
areas (24%). 
• One in 50 (2%) dosing points were located in Remote or Very remote areas (Table 4.2). 
Table 4.2: Dosing points by geographic location(a)(b) and jurisdiction, 2011–12 
Location NSW Vic Qld WA SA Tas ACT NT Australia 
  Number 
Major cities 474 307 226 169 130 — 31 — 1,337 
Inner regional 210 127 114 27 26 36 2 — 542 
Outer regional 68 24 96 25 35 19 — 8 275 
Remote 8 1 10 9 5 — — 2 35 
Very remote 3 — 6 4 3 — — — 16 
Not reported 2 — 17 2 — — — — 21 
Total(c) 764 458 470 237 199 55 33 10 2,226 
  Per cent 
Major cities 62.0 67.0 48.1 71.3 65.3 — 93.9 — 60.1 
Inner regional 27.5 27.7 24.3 11.4 13.1 65.5 6.1 — 24.3 
Outer regional 8.9 5.2 20.4 10.5 17.6 34.5 — 80.0 12.4 
Remote 1.0 0.2 2.1 3.8 2.5 — — 20.0 1.6 
Very remote 0.4 — 1.3 1.7 1.5 — — — 0.7 
Not reported 0.3 — 3.6 0.8 — — — — 0.9 
Total(c) 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
(a) The geographic location of treatment agencies has been analysed using the 2011 Remoteness Structure of the ABS Australian Standard 
Geographical Classification. 
(b) Some remoteness areas are not found in all states and territories. 
(c) Number of dosing points may not sum to total due to rounding. 
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4.2 Where do clients receive their pharmacotherapy 
drugs? 
Of the 46,697 clients receiving treatment on the snapshot day in June 2012, the majority (71%) 
dosed at a pharmacy. Other common sites for dosing were private and public clinics (8% of 
clients each) and correctional facilities (7%) (Table A14).  
Clients per dosing point 
On the snapshot day in June 2012, an average of 21 clients dosed at each dosing point site. 
However, this varied greatly by the type of dosing point. For example, each private clinic 
dosed, on average, more than 10 times as many clients as each pharmacy (186 clients per 
dosing point compared to 17). Each correctional setting dosed an average of 111 clients, but 
this number is inflated because New South Wales reports all correctional dosing point sites 
under a single facility. If New South Wales data are excluded, each correctional setting dosed 
an average of 57 clients (Figure 4.1). 
 
Note: NSW reports all correctional dosing point sites under a single facility. 
Source: Tables 4.1 and A15. 
Figure 4.1: Ratio of clients to dosing point sites, on a snapshot day, 2012 
Nationally, the ratio of clients per dosing point rose from 18.7 in 2006 to 20.9 in 2010, and 
remained at around 21 in 2011 and 2012. At a state and territory level, the ratio of clients per 
dosing point rose or remained relatively stable between 2006 and 2012 in most jurisdictions. 
However, the ratio of clients per dosing point fell slightly in Tasmania (from 12.5 in 2006 to 
11.4 in 2012) and the Northern Territory (from 13.4 in 2006 to 12.1 in 2012) (Figure 4.2). 
In 2012, Victoria had the highest ratio of clients per dosing point (30.6), followed by the 
Australian Capital Territory (27.1) and New South Wales (24.5) (Figure 4.2). It is possible that 
the higher prevalence of pharmacotherapy clients (see Chapter 2.1) and the larger proportion 
of dosing points in Major cities or Inner regional areas in these jurisdictions allowed more 
clients to attend each dosing point. 
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Note: 2011 dosing point numbers have been revised for Vic and are different from previous publications. This also affects the Australian total. 
Source: Table A11. 
Figure 4.2: Ratio of clients to dosing points, by state and territory, on a snapshot day, 2006–2012 
Drug type 
While the majority of clients were dosed at pharmacies, a larger proportion of clients who 
received buprenorphine–naloxone were dosed at a pharmacy (86%) than those receiving 
methadone (70%) or buprenorphine only (52%). A larger proportion of clients who received 
methadone were dosed in a correctional setting (9%) than those who received buprenorphine 
only (3%) or buprenorphine–naloxone only (2%) (Figure 4.3). These proportions are similar 
to those observed in 2011 (Table A14).  
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Notes 
1. NSW counts buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
2. The category ‘Other’ includes mobile dosing sites, non-government organisations, doctors’ surgeries and dosing points ‘not stated’. 
3. In Qld, the category ‘Not reported’ refers to clients who received their pharmacotherapy drug at a dosing point before the 
‘snapshot/specified’ day—that is, they received a takeaway dose. In SA, ‘Not reported’ refers to clients registered to receive treatment but 
who failed to dose. 
Source: Table A14. 
Figure 4.3: Clients, by pharmacotherapy type and dosing point site, on a snapshot day, 2012 
Table A15 provides a further breakdown of clients by pharmacotherapy type, dosing points, 
and state and territory. 
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5 The opioid pharmacotherapy system in 
Australia 
A brief overview of the Australian opioid pharmacotherapy system was given in Chapter 1. 
The states and territories administer the system, and this chapter has further information 
about the different policies and guidelines in each jurisdiction. Specific information 
pertaining to each jurisdiction is in tables 5.1, 5.2 and 5.3. 
Prescribers 
Each state and territory has rules about how prescribers are authorised to prescribe 
methadone, buprenorphine and buprenorphine–naloxone. Each runs professional training 
programs for medical personnel wishing to be approved as prescribers (DoHA 2007). In 
some states and territories, doctors can be authorised to prescribe to up to 5 ongoing clients 
without attending a training course, if these clients have first been seen by a medical 
practitioner with accredited training (ACT Health 2009; NSW Health 2006). In South 
Australia, medical practitioners can treat up to 5 new or ongoing clients with 
buprenorphine–naloxone film without undertaking training (SA Health 2011). 
Being authorised or registered to prescribe pharmacotherapy for opioid dependence does 
not necessarily mean that the prescriber will prescribe this medication during any given 
year. Prescribers who have prescribed pharmacotherapy for a client with opioid dependence 
in a given financial year are referred to as ‘active prescribers’ (Box 1.3). 
Dosing 
At the start of treatment, clients need to attend the clinic or pharmacy to take their dose 
under supervision. However, the requirement to travel regularly to the dosing point can be a 
barrier to both ongoing participation in treatment and social reintegration. To overcome 
these issues, there is a provision for takeaway doses for stable clients in some circumstances 
(DoHA 2007). Policies on takeaway dosing vary by state or territory (for more information 
refer to the individual state and territory guidelines for treating opioid dependence in Table 
5.3). Where takeaway dosing is allowed, it is preferred that clients on buprenorphine are 
given the combination buprenorphine–naloxone product (DoHA 2007). 
Cost to clients 
Depending on the state or territory and the dosing point type (Box 1.3), opioid 
pharmacotherapy for clients can be either free or charged. Under the provisions of the PBS 
for the Opiate Dependence Treatment Program, the drugs are provided free to dosing points. 
Clients may be charged a dispensing fee when receiving medication. This cost may limit 
clients’ access to opioid pharmacotherapy (Ritter & Chalmers 2009). In most cases, dosing at 
public clinics is free, at least for a limited time (see Table 5.3). 
Data collection by states and territories 
Each state and territory uses a slightly different method to collect data about the 
pharmacotherapy used to treat those with opioid dependence. These are driven by 
differences between the states and territories in relation to legislation, information 
  National Opioid Pharmacotherapy Statistics Annual Data Collection 2012 29 
technology systems and resources. The differences may result in discrepancies when 
comparing one state or territory with another. Differing administrative features adopted by 
each state and territory are outlined in Table 5.1 and methodological features are in Table 5.2. 
State and territory differences are also highlighted in the footnotes under the relevant tables. 
Table 5.1: Administrative features of the NOPSAD collection in each state and territory 
State/territory  Administrative features  
New South Wales The Pharmaceutical Drugs of Addiction System (PHDAS) is used primarily in the administration of the 
New South Wales Opioid Treatment Program. The database is used to record the authorisation of 
doctors to prescribe as part of the New South Wales Opioid Treatment Program. The PHDAS also 
records client admissions to, and exits from, treatment, as well as details of approved prescribers and 
dosing points. For these reasons, the PHDAS is characterised by continual fluctuations and data 
extracted at different times for the same period may not be the same. However, while delays in 
reporting entries to the program, exits from the program and changes in the status of dosing points 
cause short-term fluctuations in the database, these flatten out over the course of a full year. 
Client data are reported in New South Wales as at 30 June. 
Victoria  Data are collected from two sources: a quarterly census of pharmacists who are requested to report 
the actual number of clients being dosed on a snapshot day, and the permit database, which records 
information about prescribers authorised to prescribe pharmacotherapy drugs, as well as demographic 
information about clients accessing pharmacotherapy treatment. These two data sources cannot be 
linked. The Victorian pharmacotherapy system is essentially community-based, other than inpatients in 
hospitals and in prisons. Although a small number of services receive government funding, services 
are independent bodies and are not managed directly by government. 
Client data are reported in Victoria on a snapshot day.  
Queensland  Data are collected monthly from pharmacists and entered into a central database managed by 
Medicines Regulation and Quality. Data are also collected from administrative ‘Admission’ and 
‘Discharge’ forms. National and Queensland totals may vary slightly due to these data source 
differences. For example, a client may be counted as registered and having received a dose on the 
snapshot day, but a dosing point cannot be assigned because the dose consumed on that day was a 
takeaway dose. 
Client data are reported in Queensland on a snapshot day.  
Western Australia  Data are collected from the monthly reports received from pharmacies and other dosing sites 
authorised to participate in the Community Program for Opioid Pharmacotherapy (C-POP). The dosing 
data are entered into the Pharmaceutical Services Branch’s Monitoring of Drugs of Dependence 
System (MODDS) database. Data are also collected from the ‘Application for authority’, ‘Authority to 
prescribe’ and ‘Termination of treatment’ forms. 
Client data are reported in Western Australia for the entire month of June. Specifically, pharmacies 
supply information at the end of June relating to the last dose supplied to the patient. If a patient 
changes pharmacies mid-month, it is possible that they appear on two pharmacies’ monthly transaction 
reports and are counted twice. Before 2005, Western Australia reported clients over a year.  
(continued) 
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Table 5.1 (continued): Administrative features of the NOPSAD collection in each state and territory 
State/territory  Administrative features  
South Australia  Data are collected from the forms ‘Application for authority’, ‘Termination of treatment’ and ‘Request for 
additional methadone/buprenorphine takeaway’, which are entered into a central database system at 
the Drugs of Dependence Unit, Medicines and Technology Policy and Programs, Department for 
Health and Ageing (SA). Information from dispensed prescriptions is also collected electronically from 
pharmacists monthly by the Drugs of Dependence Unit. 
From 2011, data have been collected via a survey twice a year completed by pharmacists and reported 
on a snapshot day. Other data are drawn from the Drugs of Dependence Unit’s Drugs of Misuse 
Surveillance System and are about those clients registered for treatment on the snapshot day (but who 
may not actually receive treatment on that day). 
From the 4th of April 2011, the Drugs of Dependence Unit introduced new policies permitting any 
medical practitioner to be authorised to prescribe buprenorphine–naloxone for up to 5 patients for the 
treatment of opioid drug dependence. This program is known as the Suboxone® Opioid Substitution 
Program (SOSP). Authorities granted by the Drugs of Dependence Unit are still required to be held 
before starting treatment with buprenorphine–naloxone, and the usual program rules for all 
pharmacotherapy programs remain in force. From September 2011, buprenorphine–naloxone film is 
the only drug option authorised for this program. A prescriber can treat up to a maximum of 5 patients 
with buprenorphine–naloxone film before having to undertake accreditation by Drug and Alcohol 
Services South Australia (DASSA) and formal approval by the Drugs of Dependence Unit to be an 
accredited prescriber via the Opioid Dependence Substitution Program (ODSP). A prescriber cannot 
provide treatment with buprenorphine alone or methadone liquid without first being accredited. 
Tasmania  Data are collected monthly from pharmacists participating in the Tasmanian Opioid Pharmacotherapy 
Program, and entered into the Drug and Alcohol Pharmacy Information System (DAPIS). This central 
database is managed through the Pharmaceutical Services Branch, and is a ‘live’ database, from 
which a snapshot for any day can be taken. Data from DAPIS are made available for management-
style reporting from an intranet-based dashboard system. 
Client data are reported in Tasmania on a snapshot day. 
Australian Capital 
Territory 
Client participation data are collected from the Health Directorate’s Alcohol and Drug Services 
databases and from prescription dosing records provided by community pharmacies. General 
practitioner and pharmacy participation data are collected from the Chief Health Officer’s records and 
quarterly phone contact. 
Client data are reported in the Australian Capital Territory on a snapshot day.  
Northern Territory  Prescribers complete an ‘Application for authority to prescribe a restricted S8 substance for the 
treatment of addiction’ and submit the form with a photograph of the client to the Department of Health, 
Poisons Control. A contract between the client, prescriber and supplying pharmacy is also required for 
all applications for maintenance treatments. The information provided is assessed against data held in 
the Drug Monitoring System database. Non-standard applications are required to be submitted to the 
S8 and Restricted S4 Substances Clinical Advisory Committee for advice before a decision can be 
made on whether to issue the authorisation and whether special conditions need to apply. The 
prescriber is not permitted to prescribe until they receive a signed authorisation document (usually 
delivered by facsimile). When the prescriber is no longer treating the client, they are required to notify 
Poisons Control—this may be done by marking the authorisation/copy of application document as 
ceased, or by other written advice. 
Client data are reported in the Northern Territory on a snapshot day. 
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Table 5.2: Methodological differences of the NOPSAD collection in each state and territory 
State/territory  Methodological notes 
New South Wales Clients prescribed buprenorphine–naloxone are counted under ‘buprenorphine’. 
Similarly, New South Wales data collection does not differentiate between prescribers who are 
authorised to prescribe buprenorphine and those authorised to prescribe buprenorphine–naloxone. 
Data relating to prescribers refer to active prescribers only. 
Prescribers authorised to prescribe methadone can additionally be approved to prescribe 
buprenorphine, but not vice versa. Medical practitioners who manage up to 5 clients do not require an 
approval to prescribe drugs of addiction under Section 28A of the Poisons and Therapeutic Goods Act 
1966 (NSW) and are not required to complete pharmacotherapy training. Those who are not 
accredited/approved prescribers may prescribe up to 5 ‘stable’ patients; that is, you may transfer a 
patient to them, but they cannot induct a person onto treatment at this time. 
In New South Wales approved and accredited prescribers can prescribe both methadone and 
buprenorphine (including buprenorphine–naloxone).  The numbers provided in Table 3.1 for New 
South Wales represent the type of drugs prescribed by active prescribers on 30 June rather than the 
number of prescribers approved to prescribe each drug type. 
Data on dosing point sites relate to sites that were dosing at least one client as at 30 June 2011. 
Victoria  The apparent uniformity of gender and age breakdown across drug types is not measured but 
estimated. These data are included in order to enable analysis, but should be treated with caution. 
The numbers of registered prescribers in Victoria have been revised and are different from data 
reported previously. The number registered to prescribe more than one drug type changed from 341 to 
314 in 2006, from 371 to 350 in 2007, from 407 to 383 in 2008, from 373 to 420 in 2009, and from 460 
to 473 in 2011. The number registered to prescribe methadone changed from 84 to 122 in 2009 and 
from 30 to 122 in 2011. 
The number of prescribers in Victoria is determined by adding the number of prescribers registered for 
that year to the number of existing prescribers. 
In 2012, the number of dosing point sites in Victoria in 2011 was revised, and is different from the 
figures previously reported. The 2011 numbers changed for pharmacy dosing sites (from 478 to 429), 
hospital dosing sites (from 29 to 17), and ‘other’ dosing sites (from 3 to 0). 
In Victoria, data relating to the Indigenous status of clients are not available.  
Queensland  The total number of prescribers for Queensland includes those from private practice, public clinics, 
correctional facilities and government medical offices. 
In 2006 and 2007, Queensland excluded clients who were not physically dosed on the snapshot day. 
In 2008 an ‘Other’ category was included to capture these clients. 
Western Australia  The number of clients receiving pharmacotherapy treatment is reported through the month of June. 
Before 2005, Western Australia reported clients over the whole year. 
Prescriber training is provided for all pharmacotherapies currently available. The total number of 
prescribers includes those treating at least one client as at 30 June 2012 in private practice, public 
clinics and correctional facilities. 
In Western Australia, data relating to the Indigenous status of clients are not available. 
South Australia  In 2008, South Australia made a slight variation to its collection methodology, which has resulted in a 
revision of the total client numbers for 2006 (from 2,517 to 2,823) and 2007 (from 2,559 to 2,834). This 
revision has also resulted in a change in the total number of clients for 2006 (from 38,659 to 38,965) 
and 2007 (from 38,568 to 38,843). 
In 2010, the drug type of 9 clients receiving pharmacotherapy was not captured—these clients were 
removed from all analyses. 
Clients who did not enter a dosing point on the snapshot day are reported as ‘other’ when describing 
clients by dosing point site.  
All tables include ODSP and SOSP clients and prescribers. 
In South Australia, data relating to prescribers refer to active prescribers only. 
Tasmania  In Tasmania, pharmacotherapy training is provided separately for each pharmacotherapy drug. 
Australian Capital 
Territory 
— 
Northern Territory  — 
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Table 5.3: Policies and guidelines for opioid pharmacotherapy in each state and territory, 2012 
State/territory  Policies and guidelines for opioid pharmacotherapy  
New South Wales • Opioid Treatment Program Clinical Guidelines 2006 for Methadone and Buprenorphine 
Treatment of Opioid Dependence  
Victoria • Policy for Maintenance Pharmacotherapy for Opioid Dependence  
Queensland • Queensland Opioid Treatment Program: clinical guidelines 2012 
Western Australia • Western Australia Clinical Policies and Procedures for the Use of Methadone and 
Buprenorphine in the Treatment of Opioid Dependence—October 2007 
• Operational Directive 0255/09 Management of C-POP Patients in a Hospital Setting 
South Australia • Information for medical practitioners acting as a locum for an accredited community ODSP 
prescriber 
• Guidelines for action to be taken in response to serious breaches of the drug treatment 
programs—ODSP and SOSP 
• Policy for non-supervised dosing of methadone and buprenorphine in drug treatment 
programs 
• Policy for split doses methadone in the ODSP 
• Policy relating to the use of buprenorphine in the ODSP 
• Protocol for drug treatment program transfer to South Australia 
• Protocol for drug treatment program transfer interstate/territory 
• Validity of a South Australia prescription for the ODSP in another state/territory 
• Validity of an interstate prescription for the ODSP in South Australia 
• SOSP Guidelines—an information handout for medical practitioners in South Australia 
• Information for a prescriber acting in the absence of the Authority holder (paediatrician) 
accredited to treat Neonatal Abstinence Syndrome (NAS) 
Tasmania • Tasmanian Opioid Pharmacotherapy Policy and Clinical Practice Standards, 2012 
Australian Capital Territory • The ACT Opioid Maintenance Treatment Guidelines 
Northern Territory • Northern Territory Schedule 8 and Restricted Schedule 4 Substances Policy and Clinical 
Practice Guidelines 
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Appendix A: Additional tables  
Table A1: Clients receiving pharmacotherapy, by state and territory, on a snapshot day, 1998–2012 
Year NSW Vic Qld WA(a) SA(a) Tas ACT NT Australia 
Clients per 
10,000 
population, 
Australia 
1998 12,107 5,334 3,011 1,654 1,839 306 406 — 24,657 13 
1999 12,500 6,700 3,341 2,449 1,985 370 559 2 27,906 15 
2000 13,594 7,647 3,588 2,140 2,198 423 615 32 30,237 16 
2001 15,069 7,743 3,745 2,307 2,522 464 641 25 32,516 17 
2002 15,471 7,700 3,896 3,602 2,417 513 590 21 34,210 17 
2003 16,165 8,685 4,289 4,079 2,486 498 686 98 36,986 19 
2004 15,719 10,003 4,470 4,437 2,706 576 748 82 38,741 19 
2005 16,469 10,753 4,440 2,883 2,857 588 764 183 38,937 19 
2006 16,355 10,736 4,637 2,888 2,823 602 790 134 38,965 19 
2007 16,348 11,051 4,309 2,822 2,834 600 765 114 38,843 18 
2008 17,168 11,821 4,899 2,908 3,052 588 786 125 41,347 19 
2009 17,868 12,576 5,116 3,187 3,151 634 792 121 43,445 20 
2010 19,114 13,185 5,688 3,342 3,210 620 811 108 46,078 21 
2011 18,831 13,755 5,702 3,382 3,183 645 825 123 46,446 21 
2012 18,715 14,035 5,819 3,273 3,215 626 893 121 46,697 21 
(a) See Table 5.1 and Table 5.2 for more information about WA and SA. 
Table A2: Population rates for clients receiving pharmacotherapy, by state and territory, on a 
snapshot day in 2012 (number of clients per 10,000 population) 
Jurisdiction  Clients Population Clients per 10,000 population 
NSW 18,715 7,290,345 26 
Vic 14,035 5,623,492 25 
Qld 5,819 4,560,059 13 
WA 3,273 2,430,252 13 
SA 3,215 1,654,778 19 
Tas 626 512,019 12 
ACT 893 374,658 24 
NT 121 234,836 5 
Australia 46,697 22,683,573 21 
Source: ABS Australian Demographic Statistics, June 2012. 
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Table A3: Clients, by pharmacotherapy type, and state and territory, on a snapshot day, 2012 
Pharmacotherapy drug type NSW Vic Qld WA(a) SA Tas ACT NT Australia 
 
Number 
Methadone 14,245 9,330 3,001 2,183 1,887 320 735 36 31,737 
Buprenorphine(b) 4,470 584 795 96 255 67 36 14 6,317 
Buprenorphine–naloxone n.a. 4,121 2,023 994 1,073 239 122 71 8,643 
Total 18,715 14,035 5,819 3,273 3,215 626 893 121 46,697 
 
Per cent 
Methadone 76.1 66.5 51.6 66.7 58.7 51.1 82.3 29.8 68.0 
Buprenorphine(b) 23.9 4.2 13.7 2.9 7.9 10.7 4.0 11.6 13.5 
Buprenorphine–naloxone n.a. 29.4 34.8 30.4 33.4 38.2 13.7 58.7 18.5 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
Per cent of all clients 40.1 30.1 12.5 7.0 6.9 1.3 1.9 0.3 100.0 
(a) See Table 5.1 and Table 5.2 for more information about WA. 
(b) NSW counts Buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
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Table A4: Clients, by pharmacotherapy type, and state and territory, on a snapshot day, 2006–2011 
(per cent)  
Pharmacotherapy drug type NSW Vic Qld WA(a) SA Tas ACT NT Australia 
  2011 
Methadone 77.8 65.7 52.5 67.1 61.5 65.0 79.9 25.2 68.9 
Buprenorphine(b) 22.2 4.7 15.4 4.0 11.0 8.7 5.5 15.4 13.6 
Buprenorphine–naloxone n.a. 29.6 32.1 28.9 27.4 26.4 14.7 59.3 17.5 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
Per cent of all clients 40.5 29.6 12.3 7.3 6.9 1.4 1.8 0.3 100.0 
  2010 
Methadone 78.7 64.3 53.7 67.9 60.6 69.7 77.9 31.5 69.2 
Buprenorphine(b) 21.3 6.2 14.0 3.8 13.4 8.2 7.4 13.9 13.8 
Buprenorphine–naloxone — 29.5 32.3 28.3 26.0 22.1 14.7 54.6 17.0 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
Per cent of all clients 41.5 28.6 12.3 7.3 7.0 1.3 1.8 0.2 100.0 
 
2009 
Methadone 80.7 62.5 55.0 68.2 62.0 74.4 78.9 38.8 70.1 
Buprenorphine(b) 19.3 8.5 14.7 4.6 14.9 11.8 7.1 14.0 13.8 
Buprenorphine–naloxone n.a. 29.0 30.3 27.2 23.1 13.7 14.0 47.1 16.1 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
Per cent of all clients 41.1 28.9 11.8 7.3 7.3 1.5 1.8 0.3 100.0 
  2008 
Methadone 81.4 60.6 56.1 68.6 63.2 81.6 76.0 39.2 70.0 
Buprenorphine(b) 18.6 10.2 14.1 6.2 18.5 9.2 11.3 18.4 14.5 
Buprenorphine–naloxone n.a. 29.2 29.9 25.2 18.3 9.2 12.7 42.4 15.5 
Total 100.0 100.0 100.1 100.0 100.0 100.0 100.0 100.0 100.0 
Per cent of all clients 41.5 28.6 11.8 7.0 7.4 1.4 1.9 0.3 100.0 
 
2007 
Methadone 83.2 60.0 62.1 69.3 64.2 85.3 79.3 42.1 71.7 
Buprenorphine(b) 16.8 14.0 37.9 8.7 21.7 12.2 10.8 29.8 18.0 
Buprenorphine–naloxone n.a. 26.0 — 21.9 14.1 2.5 9.8 28.1 10.3 
Total 100.0 100.0 100.0 99.9 100.0 100.0 99.9 100.0 100.0 
Per cent of all clients 42.4 28.7 11.2 7.3 6.6 1.6 2.0 0.3 100.0 
 
2006 
Methadone 83.9 59.6 61.2 64.8 62.5 86.5 75.9 53 71.4 
Buprenorphine(b) 16.1 26.8 38.8 18.8 30.9 13.5 24.1 30.6 23.2 
Buprenorphine–naloxone n.a. 13.6 — 16.4 6.6 — — 16.4 5.5 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
Per cent of all clients 42.3 27.8 12.0 7.5 6.5 1.6 2.0 0.3 100.0 
(a) See Table 5.1 and Table 5.2 for more information about WA. 
(b) NSW counts Buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
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Table A5: Clients, by sex and pharmacotherapy type, on a snapshot day, 2006–2012 
Sex Methadone Buprenorphine(a) 
Buprenorphine–
naloxone Total 
 
2012 (number) 
Males 20,360 4,156 5,687 30,203 
Females 11,329 2,158 2,935 16,422 
Not stated 48 3 21 72 
Total 31,737 6,317 8,643 46,697 
 
2012 (per cent) 
Males 64.2 65.8 65.8 64.7 
Females 35.7 34.2 34.0 35.2 
Not stated 0.2 0.0 0.2 0.2 
Total 100.0 100.0 100.0 100.0 
 
2011 (per cent) 
Males 64.3 66.0 66.4 64.9 
Females 35.4 33.9 33.2 34.8 
Not stated 0.3 0.1 0.4 0.3 
Total 100.0 100.0 100.0 100.0 
 
2010 (per cent) 
Males 64.3 66.5 62.6 64.9 
Females 35.5 33.4 37.0 34.9 
Not stated 0.2 0.1 0.3 0.2 
Total 100.0 100.0 100.0 100.0 
 
2009 (per cent) 
Males 64.1 67.1 66.4 64.9 
Females 35.7 32.8 33.2 34.9 
Not stated 0.2 0.1 0.4 0.2 
Total 100.0 100.0 100.0 100.0 
 
2008 (per cent) 
Males 63.4 67 66.7 64.4 
Females 36.1 32.8 32.6 35.1 
Not stated 0.5 0.3 0.7 0.5 
Total 100.0 100.0 100.0 100.0 
 
2007 (per cent) 
Males 63.1 66.5 66.6 64.1 
Females 36.4 33.1 32.6 35.4 
Not stated 0.5 0.4 0.8 0.5 
Total 100.0 100.0 100.0 100.0 
 
2006 (per cent) 
Males 62.8 67.9 65.5 64.2 
Females 36.8 31.6 33.3 35.4 
Not stated 0.3 0.5 1.1 0.4 
Total 100.0 100.0 100.0 100.0 
(a) NSW counts Buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
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Table A6: Clients, by age group and pharmacotherapy type, on a snapshot day, 2006–2012 (per cent) 
Age group Methadone Buprenorphine(a) 
Buprenorphine–
naloxone Total  
 
2012 
29 years or less 11.8 15.2 15.5 13.0 
30–39 years 37.5 40.9 44.2 39.2 
40–49 years 30.8 28.6 28.0 30.0 
50–59 years 17.8 13.6 10.8 15.9 
60 years and over 2.0 1.7 1.3 1.8 
Not stated 0.1 — 0.1 0.1 
Total 100.0 100.0 100.0 100.0 
  2011 
29 years or less 14.0 17.4 18.0 15.1 
30–39 years 38.3 41.1 44.4 39.7 
40–49 years 30.0 27.6 26.3 29.0 
50–59 years 16.2 12.3 10.0 14.6 
60 years and over 1.6 1.3 1.0 1.4 
Not stated — 0.3 0.2 0.1 
Total 100.0 100.0 100.0 100.0 
  2010 
29 years or less 16.9 19.8 21.8 18.1 
30–39 years 38.3 42.0 44.4 39.8 
40–49 years 29.2 26.6 23.9 27.9 
50–59 years 14.6 10.7 9.0 13.1 
60 years and over 1.1 0.9 0.7 1.0 
Not stated — — 0.1 0.01 
Total 100.0 100.0 100.0 100.0 
  2009 
29 years or less 16.6 21.7 20.3 17.9 
30–39 years 38.6 41.8 44.5 40.0 
40–49 years 30.1 26.0 25.5 28.8 
50–59 years 13.9 9.7 8.9 12.5 
60 years and over 0.9 0.7 0.7 0.8 
Total  100.0 100.0 100.0 100.0 
 
2008 
29 years or less 21.2 27.7 28.7 23.3 
30–39 years 36.9 40.1 42.5 38.2 
40–49 years 29.3 23.5 21.9 27.3 
50–59 years 12.0 8.1 6.4 10.6 
60 years and over 0.6 0.5 0.5 0.5 
Total 100.0 100.0 100.0 100.0 
 
2007 
29 years or less 20.8 27.5 25.3 22.5 
30–39 years 37.4 40.4 44.3 38.6 
40–49 years 30.1 24.0 22.6 28.3 
50–59 years 11.2 7.6 7.2 10.1 
60 years and over 0.5 0.5 0.6 0.5 
Total 100.0 100.0 100.0 100.0 
 
2006 
29 years or less 25.5 35.1 36.6 28.4 
30–39 years 36.2 38.4 40.3 36.9 
40–49 years 29.3 21.1 18.8 26.9 
50–59 years 8.7 5.1 4.2 7.6 
60 years and over 0.3 0.3 0.2 0.3 
Total 100.0 100.0 100.0 100.0 
(a) NSW counts Buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
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Table A7: Clients, by age group, pharmacotherapy type and state and territory, on a snapshot day, 
2012 
Age group NSW Vic Qld WA SA Tas ACT NT Australia 
Australia  
(per cent) 
 
Methadone 
29 years or less 1,460 1,411 294 215 202 24 144 n.p. 3,750 11.8 
30–39 years 4,741 4,173 1,054 903 588 147 271 19(b) 11,896 37.5 
40–49 years 4,654 2,597 911 641 662 100 201 11 9,777 30.8 
50 years and over 3,390 1,132 741 424 435 49 119 6 6,296 19.8 
Not stated — 17 1 — — — — — 18 0.1 
Total 14,245 9,330 3,001 2,183 1,887 320 735 17 31,737 100.0 
Median age (years) 41 37 41 39 41 39 38 39 40 . . 
 
Buprenorphine(a) 
29 years or less 701 89 113 18 26 13 3 — 963 15.2 
30–39 years 1,760 260 388 47 76 31 14 7 2,583 40.9 
40–49 years 1,308 163 187 26 89 15 13 3 1,804 28.6 
50 years and over 701 71 107 5 64 8 6 4 966 15.3 
Not stated — 1 — — — — — — 1 <0.1 
Total 4,470 584 795 96 255 67 36 14 6,317 100.0 
Median age (years) 38 37 37 34 42 36 40 45 38 . . 
 
Buprenorphine–naloxone 
29 years or less n.a. 625 336 134 172 48 12 15 1,342 15.5 
30–39 years n.a. 1,842 889 447 447 113 54 30 3,822 44.2 
40–49 years n.a. 1,148 544 279 332 67 37 17 2,424 28.0 
50 years and over n.a. 498 250 134 122 11 19 9 1,043 12.1 
Not stated n.a. 8 4 — — — — — 12 0.1 
Total n.a. 4,121 2,023 994 1,073 239 122 71 8,643 100.0 
Median age (years) n.a. 37 37 37 38 35 38 37 37 . . 
 
Total (all pharmacotherapy drugs) 
29 years or less 2,161 2,125 743 367 400 85 159 15 6,055 13.0 
30–39 years 6,501 6,275 2,331 1,397 1,111 291 339 56 18,301 39.2 
40–49 years 5,962 3,908 1,642 946 1,083 182 251 31 14,005 30.0 
50 years and over 4,091 1,701 1,098 563 621 68 144 19 8,305 17.8 
Not stated — 26 5 — — — — — 31 0.1 
Total 18,715 14,035 5,819 3,273 3,215 626 893 121 46,697 100.0 
Median age (years) 40 37 39 38 40 37 38 38 39 . . 
(a) NSW counts Buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
(b) Refers to clients aged 29 years or less and 30–39 years. The number aged 29 years or less is small (<3). 
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Table A8: Registered prescribers(a), by pharmacotherapy type, and state and territory, 2005–2011 
Pharmacotherapy drug type NSW Vic(c)  Qld WA SA Tas ACT NT Australia 
Australia  
(per cent) 
 
2011 
Methadone only 214 122 — — — 10 — — 346 22.3 
Buprenorphine only(b) 58 — — — — 1 — — 59 3.8 
Buprenorphine–naloxone only n.a.  — — — 13 3 — — 16 1.0 
More than one drug type 285 473 105 116 72 21 47 9 1,128 72.8 
Total (number) 557 595 105 116 85 35 47 9 1,549 100.0 
Total (per cent) 36.0 38.4 6.8 7.5 5.5 2.3 3.0 0.6 100.0 . . 
 
2010 
Methadone only 214 122 1 — — — — — 337 23.3 
Buprenorphine only(b) 34 — — — — — — — 34 2.3 
Buprenorphine–naloxone only n.a. — 1 — — — — — 1 0.1 
More than one drug type 266 444 103 108 77 30 39 10 1,077 74.3 
Total (number) 514 566 105 108 77 30 39 10 1,449 100.0 
Total (per cent) 35.5 39.1 7.2 7.5 5.3 2.1 2.7 0.7 100.0 . . 
 
2009 
Methadone only 228 122 4 — — 12 9 — 375 26.1 
Buprenorphine only(b) 58 — 1 — — — — — 59 4.1 
Buprenorphine–naloxone only n.a. — 1 — — — — — 1 0.1 
More than one drug type 242 420 115 92 73 23 27 8 1,000 69.7 
Total (number) 528 542 121 92 73 35 36 8 1,435 100.0 
Total (per cent) 36.8 37.8 8.4 6.4 5.1 2.4 2.5 0.6 100.0 . . 
 
2008 
Methadone only 199 122 2 14 — 24 10 — 371 27.1 
Buprenorphine only(b) 39 — 1 — — 18 — — 58 4.2 
Buprenorphine–naloxone only n.a. — 1 — — 5 — — 6 0.4 
More than one drug type 257 383 107 69 74 5 26 13 934 68.2 
Total (number) 495 505 111 83 74 52 36 13 1,369 100.0 
Total (per cent) 36.2 36.9 8.1 6.1 5.4 3.8 2.6 0.9 100.0 . . 
 
2007 
Methadone only 176 122 2 15 — 29 11 — 355 27.9 
Buprenorphine only(b) 30 — 5 1 — 18 — — 54 4.2 
Buprenorphine–naloxone only n.a. — — — — 5 — — 5 0.4 
More than one drug type 246 350 92 70 74 — 14 14 860 67.5 
Total (number) 452 472 99 86 74 52 25 14 1,274 100.0 
Total (per cent) 35.5 37.0 7.8 6.8 5.8 4.1 2.0 1.1 100.0 . . 
(continued) 
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Table A8 (continued): Registered prescribers(a), by pharmacotherapy type, and state and territory, 
2005–2011 
Pharmacotherapy drug type NSW Vic(c)  Qld WA SA Tas ACT NT Australia 
Australia  
(per cent) 
 
2006(d) 
Methadone only 123 122 9 15 — — 13 — 282 23.6 
Buprenorphine only(b) 287 — 5 1 — — 12 — 305 25.6 
Buprenorphine–naloxone only n.a. — — — — — — — — — 
More than one drug type — 314 120 52 65 48 — 7 606 50.8 
Total (number) 410 436 134 68 65 48 25 7 1,193 100.0 
Total (per cent) 34.4 36.5 11.2 5.7 5.4 4.0 2.1 0.6 100.0 . . 
 
2005(d)(e) 
Methadone only 123 112 10 15 — 42 13 — 315 25.5 
Buprenorphine only(b) — — 1 1 — — — — 2 0.2 
Methadone and buprenorphine 293 316 114 56 73 39 15 11 917 74.3 
Total (number) 416 428 125 72 73 81 28 11 1,234 100.0 
Total (per cent) 33.7 34.7 10.1 5.8 5.9 6.6 2.3 0.9 100.0 . . 
(a) The states and territories may have different guidelines and policies regarding training to prescribe the pharmacotherapy types for opioid 
dependence. Please contact their respective health departments for specific information. 
(b) NSW counts Buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
(c) 2011 prescriber numbers have been revised for Vic and are different from previous publications. 
(d) Data on ‘buprenorphine–naloxone only’ prescribers were not reported in 2005 and 2006. However, in 2006, buprenorphine–naloxone was 
available for prescription but no instances of ‘buprenorphine–naloxone only’ prescribers were reported. 
(e) ‘Authorised to prescribe more than one drug type’ was not a valid response code in 2005. 
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Table A9: Clients, by pharmacotherapy type and prescriber type, on a snapshot day, 2005–2012 
Prescriber type Methadone Buprenorphine(a) 
Buprenorphine–
naloxone Total 
 
2012 (number) 
Public prescriber(c) 8,386 2,428 2,069 12,883 
Private prescriber(c) 20,471 3,617 6,402 30,490 
Public/private prescriber(b) 183 79 — 262 
Correctional facilities(c) 2,697 193 172 3,062 
Total 31,737 6,317 8,643 46,697 
 
2012 (per cent) 
Public prescriber 26.4 38.4 23.9 27.6 
Private prescriber 64.5 57.3 74.1 65.3 
Public/private prescriber(b) 0.6 1.3 — 0.6 
Correctional facilities 8.5 3.1 2.0 6.6 
Total 100.0 100.0 100.0 100.0 
 
2011 (per cent) 
Public prescriber 26.6 37.9 22.3 27.4 
Private prescriber 63.4 57.7 75.7 64.8 
Public/private prescriber (b) 0.6 1.2 0.0 0.6 
Correctional facilities 9.4 3.2 2.0 7.2 
Total 100.0 100.0 100.0 100.0 
 
2010 (per cent) 
Public prescriber 27.1 37.0 22.2 27.6 
Private prescriber 61.7 58.4 75.2 63.51 
Public/private prescriber (b) 1.0 1.9 — 0.9 
Correctional facilities 10.3 2.7 2.6 7.9 
Total 100.0 100.0 100.0 100.0 
 
2009 (per cent) 
Public prescriber 27.2 33.9 20.1 26.9 
Private prescriber 61.7 60.6 77.3 64.1 
Public/private prescriber (b) 1.1 2.0 — 1.0 
Correctional facilities 10.1 3.5 2.7 8.0 
Total 100.0 100.0 100.0 100.0 
 
2008 (per cent) 
Public prescriber 27.3 31.7 20.4 26.9 
Private prescriber 62.8 63.6 76.1 65.0 
Public/private prescriber (b) 1.2 1.8 — 1.1 
Correctional facilities 8.7 2.9 3.5 7.0 
Total 100.0 100.0 100.0 100.0 
(continued) 
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Table A9 (continued): Clients, by pharmacotherapy type and prescriber type, on a snapshot day, 
2005–2012 
Prescriber type Methadone Buprenorphine(a) 
Buprenorphine–
naloxone Total 
 
2007 (per cent) 
Public prescriber 27.8 36.2 10.0 27.5 
Private prescriber 61.4 59.6 86.1 63.6 
Public/private prescriber (b) 1.3 1.2 — 1.2 
Correctional facilities 9.5 3.0 3.9 7.7 
Total 100.0 100.0 100.0 100.0 
 
2006 (per cent) 
Public prescriber 28.3 30.1 8.2 27.7 
Private prescriber 61.9 65.2 91.3 64.2 
Public/private prescriber (b) 1.4 1.0 — 1.2 
Correctional facilities 8.4 3.7 0.5 6.9 
Total 100.0 100.0 100.0 100.0 
 
2005 (per cent) 
Public prescriber 23.3 20.9 n.a. 23.5 
Private prescriber 68.7 75.9 n.a. 69.8 
Public/private prescriber (b) 0.2 0.1 n.a. 0.1 
Correctional facilities 7.8 3.0 n.a. 6.6 
Total 100.0 100.0 n.a. 100.0 
(a) NSW counts Buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
(b) In NSW, these figures relate to prescribing that cannot be separated into public or private prescribers. 
(c) To ensure that small cells are suppressed, some data were moved from ‘Correctional facilities’ to ‘Public prescriber’ or ‘Private prescriber’. 
This number was small (<10). 
Table A10: Clients, by prescriber type, on a snapshot day, 2005–2012 
Prescriber type 2005 2006 2007 2008 2009 2010 2011 2012 
Public prescriber 9,133 10,794 10,695 11,106 11,705 12,735 12,711 12,883(b) 
Private prescriber 27,192 25,018 24,700 26,878 27,838 29,265(a) 30,093(a) 30,490(b) 
Public/private prescriber(c) 58 473 453 464 448 428 275 262 
Correctional facilities 2,554 2,680 2,995 2,899 3,454 3,650(a) 3,367(a) 3,062(b) 
Total 38,937 38,965 38,843 41,347 43,445 46,078 46,446 46,697 
(a) To ensure that small cells are suppressed, some data were moved from ‘Correctional Facilities’ to ‘Private Prescriber’. This number was 
small (<6). 
(b) To ensure that small cells are suppressed, some data were moved from ‘Correctional facilities’ to ‘Public prescriber’ or ‘Private prescriber’. 
This number was small (<10). 
(c) In NSW, these figures relate to prescribing that cannot be separated into public or private prescribers. 
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Table A11: Clients, prescribers and dosing point sites by state and territory, 2005–2012 
  NSW Vic(a) Qld WA SA Tas ACT NT Australia 
 
2012 
 
Number 
Total number of clients 18,715 14,035 5,819 3,273 3,215 626 893 121 46,697 
Total number of prescribers 593 685 132 95 166 33 56 8 1,768 
Total number of dosing points 764 458 470 237 199 55 33 10 2,226 
 
Ratio 
Ratio of clients per prescriber 31.6 20.5 44.1 34.5 19.4 19.0 15.9 15.1 26.4 
Ratio of clients per dosing point 24.5 30.6 12.4 13.8 16.2 11.4 27.1 12.1 21.0 
 
2011 
 
Number 
Total number of clients 18,831 13,755 5,702 3,382 3,183 645 825 123 46,446 
Total number of prescribers 557 595 105 116 85 35 47 9 1,549 
Total number of dosing points 749 457 435 258 203 55 32 11 2,200 
 
Ratio 
Ratio of clients per prescriber 33.8 23.1 54.3 29.2 37.4 18.4 17.6 13.7 30.0 
Ratio of clients per dosing point 25.1 30.1 13.1 13.1 15.7 11.7 25.8 11.2 21.1 
 
2010 
 
Number 
Total number of clients 19,114 13,185 5,688 3,342 3,210 620 811 108 46,078 
Total number of prescribers 514 566 105 108 77 30 39 10 1,449 
Total number of dosing points 732 452 479 242 197 55 31 12 2,200 
 
Ratio 
Ratio of clients per prescriber 37.2 23.3 54.2 30.9 41.7 20.7 20.8 10.8 31.8 
Ratio of clients per dosing point 26.1 29.2 11.9 13.8 16.3 11.3 26.2 9.0 20.9 
 
2009 
 
Number 
Total number of clients 17,868 12,576 5,116 3,187 3,151 634 792 121 43,445 
Total number of prescribers 528 542 121 92 73 35 36 8 1,435 
Total number of dosing points 709 436 474 247 198 54 28 11 2,157 
 
Ratio 
Ratio of clients per prescriber 33.8 23.2 42.3 34.6 43.2 18.1 22.0 15.1 30.3 
Ratio of clients per dosing point 25.2 28.8 10.8 12.9 15.9 11.7 28.3 11.0 20.1 
(continued) 
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Table A11 (continued): Clients, prescribers and dosing point sites by state and territory, 2005–2012 
  NSW Vic(a) Qld WA SA Tas ACT NT Australia 
 
2008 
 
Number 
Total number of clients 17,168 11,821 4,899 2,908 3,052 588 786 125 41,347 
Total number of prescribers 495 505 111 83 74 52 36 13 1,369 
Total number of dosing points 698 431 470 247 203 50 29 15 2,143 
 
Ratio 
Ratio of clients per prescriber 34.7 23.4 44.1 35.0 41.2 11.3 21.8 9.6 30.2 
Ratio of clients per dosing point 24.6 27.4 10.4 11.8 15.0 11.8 27.1 8.3 19.3 
 
2007 
 
Number 
Total number of clients 16,348 11,051 4,309 2,822 2,834 600 765 114 38,843 
Total number of prescribers 452 472 99 86 74 52 25 14 1,274 
Total number of dosing points 680 425 484 242 215 49 28 12 2,135 
 
Ratio 
Ratio of clients per prescriber 36.2 23.4 43.5 32.8 38.3 11.5 30.6 8.1 30.5 
Ratio of clients per dosing point 24.0 26.0 8.9 11.7 13.2 12.2 27.3 9.5 18.2 
 
2006 
 
Number 
Total number of clients 16,355 10,736 4,637 2,888 2,823 602 790 134 38,965 
Total number of prescribers 410 436 134 68 65 48 25 7 1,193 
Total number of dosing points 660 413 503 244 175 48 28 10 2,081 
 
Ratio 
Ratio of clients per prescriber 39.9 24.6 34.6 42.5 43.4 12.5 31.6 19.1 32.7 
Ratio of clients per dosing point 24.8 26.0 9.2 11.8 16.1 12.5 28.2 13.4 18.7 
 
2005 
 
Number 
Total number of clients 16,469 10,753 4,440 2,883 2,857 588 764 183 38,937 
Total number of prescribers 416 428 125 72 73 81 28 11 1,234 
 
Ratio 
Ratio of clients per prescriber 39.6 25.1 35.5 40.0 39.1 7.3 27.3 16.6 31.6 
(a) 2011 prescriber and dosing point numbers have been revised for Vic and are different from previous publications. 
Note: This table has been derived from tables A1, A8 and A13.  
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Table A12: Ratio(a) of clients to prescriber, by prescriber type, and state and territory, 2012 
Prescriber type NSW(b)(c) Vic  Qld WA SA(c) Tas ACT NT Australia 
Public Prescriber 44.9 — 114.4 61.4 85.8 24.0 173.7 20.6 58.0 
Private Prescriber 25.9 19.7 25.5 26.6 12.4 17.0 5.7 8.0 20.9 
Public/Private Prescriber 9.0 — — — — — —(d) — 8.2 
Correctional Facilities 74.6 48.2 4.2 31.4 51.4 0.5 94.0 2.0 45.8 
Total 31.6 20.5 44.1 34.5 19.4 19.0 15.9 15.1 26.2 
(a) This ratio was calculated using the formula: number of clients by all pharmacotherapy types, prescriber type and state/territory (Table 3.3) 
divided by registered prescribers by prescriber type and state/territory (Table 3.2). 
(b) NSW has prescribers who prescribe in more than one location, and as such are counted twice. This will lead to slightly deflated client to 
prescriber ratios. This occurs in NSW for 7 prescribers. 
(c) See Table 5.2 for more information about NSW and SA reporting of registered prescribers. 
(d) The number of clients that receive treatment from a public/private prescriber in the ACT are not reported in this collection. 
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Table A13: Dosing point sites, by state and territory, 2005–06 to 2010–11 
Dosing point sites NSW(a) Vic(b) Qld WA SA Tas ACT NT Australia 
Australia 
(per cent) 
 
2010–11 
Public clinic 37 — 11 1 2 1 1 3 56 2.5 
Private clinic 17 — — — — — — — 17 0.8 
Pharmacy 618 429 357 249 190 52 30 7 1,932 87.8 
Correctional setting 2 11 4 2 8 1 1 1 30 1.4 
Other(c) 75 17 63 6 3 1 — — 165 7.5 
Total (number) 749 457 435 258 203 55 32 11 2,200 100.0 
Total (per cent) 34.0 20.8 19.8 11.7 9.2 2.5 1.5 0.5 100.0 . . 
 
2009–2010 
Public clinic 37 — 10 1 2 1 1 3 55 2.5 
Private clinic 12 3 — — — — — — 15 0.7 
Pharmacy 601 421 355 234 184 53 29 7 1,884 85.6 
Correctional setting 1 10 11 2 8 1 1 2 36 1.6 
Other(c) 81 18 103 5 3 — — — 210 9.5 
Total (number) 732 452 479 242 197 55 31 12 2,200 100.0 
Total (per cent) 33.3 20.5 21.8 11.0 9.0 2.5 1.4 0.5 100.0 . . 
 
2008–2009 
Public clinic 37 — 10 1 2 1 1 2 54 2.5 
Private clinic 12 3 — — — — — — 15 0.7 
Pharmacy 572 407 354 235 185 52 26 7 1,838 85.2 
Correctional setting 1 10 12 2 9 1 1 2 38 1.8 
Other(c) 87 16 98 9 2 — — — 212 9.8 
Total (number) 709 436 474 247 198 54 28 11 2,157 100.0 
Total (per cent) 32.9 20.2 22.0 11.5 9.2 2.5 1.3 0.5 100.0 . . 
 
2007–2008 
Public clinic 37 — 10 1 2 1 1 3 55 2.6 
Private clinic 12 3 — — — — — — 15 0.7 
Pharmacy 558 403 353 233 189 48 26 10 1,820 84.9 
Correctional setting 2 10 16 2 10 1 2 2 45 2.1 
Other(c) 89 15 91 11 2 — — — 208 9.7 
Total (number) 698 431 470 247 203 50 29 15 2,143 100.0 
Total (per cent) 32.6 20.1 21.9 11.5 9.5 2.3 1.4 0.7 100.0 . . 
(continued) 
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Table A13 (continued): Dosing point sites, by state and territory, 2005–06 to 2010–11 
Dosing point sites NSW(a) Vic(b) Qld WA SA Tas ACT NT Australia 
Australia 
(per cent) 
 
2006–2007 
Public clinic 37 — 12 1 2 1 1 2 56 2.6 
Private clinic 12 3 — — — — — — 15 0.7 
Pharmacy 547 395 366 239 202 47 25 8 1,829 85.7 
Correctional setting 2 17 16 2 8 1 2 2 50 2.3 
Other(c) 82 10 90 — 3 — — — 185 8.7 
Total (number) 680 425 484 242 215 49 28 12 2,135 100.0 
Total (per cent) 31.9 19.9 22.7 11.3 10.1 2.3 1.3 0.6 100.0 . . 
 
2005–2006 
Public clinic 36 — 14 1 2 1 1 1 56 2.7 
Private clinic 12 3 — — — — — — 15 0.7 
Pharmacy 533 385 378 241 164 46 25 7 1,779 85.5 
Correctional setting 1 10 20 2 6 1 2 2 44 2.1 
Other(c) 78 15 91 — 3 — — — 187 9.0 
Total (number) 660 413 503 244 175 48 28 10 2,081 100.0 
Total (per cent) 31.7 19.8 24.2 11.7 8.4 2.3 1.3 0.5 100.0 . . 
(a) See Tables 5.1 and 5.2 for more information about NSW. 
(b) 2010–2011 dosing point site numbers have been revised for Vic and are different from previous publications. 
(c) The category ‘Other’ includes hospital inpatient and outpatients, mobile dosing sites, non-government organisations, doctors’ surgeries and 
dosing points ‘not stated’. 
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Table A14: Clients, by pharmacotherapy type and dosing point site, on a snapshot day, 2006–2012 
Dosing point site Methadone Buprenorphine(a) 
Buprenorphine–
naloxone Total 
 
2012 (number) 
Public clinic(b) 2,431 1,016 122 3,569 
Private clinic 2,600 965 153 3,718 
Pharmacy(b) 22,377 3,308 7,455 33,140 
Correctional setting(b) 2,752 201 164 3,117 
Hospital(b) 378 98 57 533 
Other(b)(c) 787 400 48 1,235 
Not reported(d) 412 329 644 1,385 
Total 31,737 6,317 8,643 46,697 
 
2012 (per cent) 
Public clinic 7.7 16.1 1.4 7.7 
Private clinic 8.2 15.3 1.8 8.0 
Pharmacy 70.5 52.3 86.2 70.9 
Correctional setting 8.7 3.2 1.9 6.7 
Hospital 1.2 1.6 0.7 1.2 
Other(c) 2.5 6.3 0.6 2.6 
Not reported(d) 1.3 5.2 7.5 3.0 
Total 100.0 100.0 100.0 100.0 
 
2011 (per cent) 
Public clinic 8.3 15.9 2.1 8.3 
Private clinic 7.3 13.4 0.0 6.8 
Pharmacy 69.3 54.8 83.5 69.8 
Correctional setting 9.3 3.2 2.1 7.2 
Hospital 1.0 1.9 0.7 1.1 
Other(c) 2.3 4.9 0.4 2.3 
Not reported(d) 2.4 6.0 11.2 4.5 
Total 100.0 100.0 100.0 100.0 
 
2010 (per cent) 
Public clinic 9.1 18.3 2.4 9.2 
Private clinic 7.8 14.7 0.2 7.5 
Pharmacy 66.7 53.4 83.0 67.6 
Correctional setting 10.2 2.8 2.3 7.9 
Other(c) 3.7 6.4 1.0 3.6 
Not reported(d) 2.6 4.5 11.1 4.3 
Total 100.0 100.0 100.0 100.0 
(continued) 
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Table A14 (continued): Clients, by pharmacotherapy type and dosing point site, on a snapshot day, 
2006–2012 
Dosing point site Methadone Buprenorphine(a) 
Buprenorphine–
naloxone Total 
 
2009 (per cent) 
Public clinic 9.5 16.5 2.8 9.4 
Private clinic 8.0 13.0 0.2 7.4 
Pharmacy 68.1 56.9 83.6 69.1 
Correctional setting 9.8 3.2 2.4 7.7 
Other(c) 4.6 10.4 11.1 6.4 
Total 100.0 100.0 100.0 100.0 
 
2008 (per cent) 
Public clinic 10.7 14.9 2.9 10.1 
Private clinic 8.4 12.7 0.2 7.7 
Pharmacy 67.6 59.8 86.9 69.4 
Correctional setting 8.8 2.9 3.0 7.1 
Other(c) 4.5 9.7 7.0 5.7 
Total 100.0 100.0 100.0 100.0 
 
2007 (per cent) 
Public clinic 11.9 14.2 2.2 10.8 
Private clinic 8.9 9.8 0.7 8.8 
Pharmacy 67.1 69.6 93.0 68.9 
Correctional setting 9.3 2.7 4.1 8.9 
Other(c) 2.8 3.7 — 2.7 
Total 100 100 100 100 
 
2006(e) (per cent) 
Public clinic 12.9 12.7 1.5 12.3 
Private clinic 9.3 8.5 1.8 8.7 
Pharmacy 67.4 73.9 94.5 70.4 
Correctional setting 8.5 3.5 2.2 7 
Other(c) 1.9 1.5 — 1.7 
Total 100 100 100 100 
(a) NSW counts Buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
(b) To ensure that small cells are suppressed, some data were moved between public clinic, pharmacy, correctional setting, hospital and other. 
This number was small (<15). 
(c) The category ‘Other’ includes mobile dosing sites, non-government organisations, doctors’ surgeries and dosing points ‘not stated’. From 
2009 and earlier ‘Other’ also includes ‘not reported’. 
(d) In Qld, the category ‘Not reported’ refers to clients who received their pharmacotherapy drug at a dosing point before the 
‘snapshot/specified’ day—that is, they received a takeaway dose. In SA, ‘Not reported’ refers to clients registered to receive treatment but 
who failed to dose. 
(e) The total estimated number of clients reported in 2006 excludes pharmacotherapy clients in the NT as data relating to dosing point sites and 
clients were not available. 
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Table A15: Clients, by pharmacotherapy type, dosing point site, and state and territory, on a 
snapshot day, 2012 
Dosing point site NSW Vic Qld WA SA Tas ACT NT Australia 
 
Methadone 
Public clinic 2,197 — 51 10 36 n.p. 137 n.p. 2,431 
Private clinic 2,276 — 324 — — — — — 2,600 
Pharmacy 7,423 8,470 2,224 1,875 1,525 320(g) 504 36(i) 22,377 
Correctional facility 1,378 808 18 291 163(f) — 94 n.p. 2,752 
Hospital 203 52 116 7 n.p. n.p. — — 378 
Other(a) 768 — 19 — n.p. — — — 787 
Not reported(b) — — 249 — 163 — — — 412 
Total 14,245 9,330 3,001 2,183 1,887 320 735 36 31,737 
 
Buprenorphine(c) 
Public clinic 974 — 8 — 7 18 9 n.p. 1,016 
Private clinic 872 — 93 — — — — — 965 
Pharmacy 1,956 584(d) 478 96 104 49(h) 27 14(i) 3,308 
Correctional facility 193 n.p. 8 — — n.p. — n.p. 201 
Hospital 90 n.p. 8 — — — — — 98 
Other(a) 385 — 15 — — — — — 400 
Not reported(b) — — 185 — 144 — — — 329 
Total 4,470 584 795 96 255 67 36 14 6,317 
 
Buprenorphine–naloxone 
Public clinic n.a. — 12 4 41 42 16 7 122 
Private clinic n.a. — 153 — — — — — 153 
Pharmacy n.a. 4,051 1,117 967(e) 957 193(h) 106 64 7,455 
Correctional facility n.a. 58 13 23 70 n.p. — — 164 
Hospital n.a. 12 41 n.p. — 4 — — 57 
Other(a) n.a. — 48 — — — — — 48 
Not reported(b) n.a. — 639 — 5 — — — 644 
Total n.a. 4,121 2,023 994 1,073 239 122 71 8,643 
 
Total (all pharmacotherapy drugs) 
Public clinic 3,171 — 71 14 84 60 162 7 3,569 
Private clinic 3,148 — 570 — — — — — 3,718 
Pharmacy 9,379 13,105 3,819 2,938 2,586 562 637 114 33,140 
Correctional facility 1,571 866 39 314 233 n.p. 94 n.p. 3,117 
Hospital 293 64 165 7 n.p. 4 — — 533 
Other(a) 1,153 — 82 — n.p. — — — 1,235 
Not reported(b) — — 1,073 — 312 — — — 1,385 
Total (number) 18,715 14,035 5,819 3,273 3,215 626 893 121 46,697 
(continued)  
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Table A15 (continued): Clients, by pharmacotherapy type, dosing point site, and state and territory, 
on a snapshot day, 2012 
Dosing point site NSW Vic Qld WA SA Tas ACT NT Australia 
 
Total (per cent all pharmacotherapy drugs) 
Public clinic 16.9 — 1.2 0.4 2.6 9.6 18.1 5.8 7.6 
Private clinic 16.8 — 9.8 — — — — — 8.0 
Pharmacy 50.1 93.4 65.6 89.8 80.4 89.8 71.3 94.2 71.0 
Correctional facility 8.4 6.2 0.7 9.6 7.2 n.p. 10.5 n.p. 6.7 
Hospital 1.6 0.5 2.8 0.2 n.p. 0.6 — — 1.1 
Other(a) 6.2 — 1.4 — n.p. — — — 2.6 
Not reported(b) — — 18.4 — 9.7 — — — 3.0 
Total (per cent) 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
(a) The category ‘Other’ includes mobile dosing sites, community health clinics, non-government organisations, doctors’ surgeries and dosing 
points ‘not stated’. 
(b) In Qld, the category ‘Not reported’ refers to clients who received their pharmacotherapy drug at a dosing point before the 
‘snapshot/specified’ day, that is, they received a takeaway dose. In SA, ‘Not reported’ refers to clients registered to receive treatment but 
who failed to dose. 
(c) NSW counts buprenorphine–naloxone as ‘Buprenorphine’. See Table 5.2 for further details. 
(d) Refers to the number of clients receiving treatment from a pharmacy, a correctional facility or a hospital. The number of clients by 
correctional facility or hospital is small (<3 each). 
(e) Refers to the number of clients receiving treatment from a pharmacy or a hospital. The number of clients by hospital is small (<3). 
(f) Refers to the number of clients receiving treatment from a correctional facility, a hospital, or ‘other’. The number of clients by hospital or 
‘other’ is small (<3 each). 
(g) Refers to the number of clients receiving treatment from a public clinic, pharmacy or hospital. The number of clients by public clinic or 
hospital is small (<3 each). 
(h) Refers to the number of clients receiving treatment from a pharmacy or a correctional facility. The number of clients by correctional facility is 
small (<3). 
(i) Refers to the number of clients receiving treatment from a public clinic, pharmacy or correctional facility. The number of clients by public 
clinic or correctional facility is small (<3 each). 
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Appendix B: Data quality statement 
National Opioid Pharmacotherapy Statistics Annual Data collection 2012 
Summary of key data quality issues 
• Each state and territory uses a slightly different method to collect data about the 
pharmacotherapy used to treat those with opioid dependence. These are driven by 
differences between the states and territories in relation to legislation, information 
technology systems and resources. The differences may result in discrepancies when 
comparing one state or territory with another. Differing administrative features adopted 
by each state and territory are in Table 5.1 and methodological features are in Table 5.2. 
Relevant state and territory differences are also highlighted in the footnotes under the 
relevant tables. 
• New South Wales is unable to differentiate between clients prescribed buprenorphine 
and buprenorphine–naloxone. Clients prescribed buprenorphine–naloxone are counted 
under ‘Buprenorphine’. 
• Victoria and Western Australia do not provide data in relation to the Indigenous status 
of clients. 
• In Western Australia, the number of clients receiving pharmacotherapy treatment is 
reported through the month of June. Before 2005, Western Australia reported clients over 
the whole year. 
Description 
This report is based on the NOPSAD collection, which collects information on 3 opioid 
pharmacotherapy drugs used for treating opioid dependence. These drugs are methadone, 
buprenorphine and buprenorphine–naloxone (Box 1.2). Each state and territory collects 
agreed data about clients receiving opioid pharmacotherapy on a snapshot day, usually in 
June each year. The snapshot day varies between states and territories. See Table 5.1 for 
information about the use of the snapshot day for each state and territory. 
While states and territories strive to report data consistent with agreed standards, the 
NOPSAD collection is not a national minimum data set and some discrepancies exist 
between the ways in which data are reported. These discrepancies are discussed in more 
detail in the administrative features for each state and territory (Table 5.1 and Table 5.2). 
The NOPSAD collection is one of a number of data sources that provide a picture of alcohol 
and other drug treatment services in Australia. 
Institutional environment  
The AIHW is a major national agency set up by the Australian Government under the 
Australian Institute of Health and Welfare Act 1987 to provide reliable, regular and relevant 
information and statistics on Australia’s health and welfare. It is an independent statutory 
authority established in 1987, governed by a Management Board, and accountable to the 
Australian Parliament through the Health and Ageing portfolio. 
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The AIHW aims to improve the health and wellbeing of Australians through better health 
and welfare information and statistics. It collects and reports information on a wide range of 
topics and issues, ranging from health and welfare expenditure, hospitals, disease and 
injury, and mental health, to ageing, homelessness, disability and child protection. 
The Institute also plays a role in developing and maintaining national metadata standards. 
This work contributes to improving the quality and consistency of national health and 
welfare statistics. The Institute works closely with governments and non-government 
organisations to achieve greater adherence to these standards in administrative data 
collections to promote national consistency and comparability of data and reporting. 
One of the main functions of the AIHW is to work with the states and territories to improve 
the quality of administrative data and, where possible, to compile national data sets based on 
data from each jurisdiction, to analyse these data sets and disseminate information and 
statistics. 
The Australian Institute of Health and Welfare Act 1987, in conjunction with compliance to the 
Privacy Act 1988 (Cth), ensures that the data collections managed by the AIHW are kept 
securely and under the strictest conditions with respect to privacy and confidentiality. 
For further information see the AIHW website <www.aihw.gov.au/>. 
Timeliness 
Data are collected by states and territories on a snapshot day, usually in June. Jurisdictions 
receive, collate and clean this data, providing it in aggregate form to the AIHW between 
October and December each year. The AIHW then analyses and reports on these data, with 
annual data available six months after the finalisation of the national data set, usually in 
June. 
Accessibility 
Results from the collection are published in an annual report that can be accessed via the 
AIHW Website. An accompanying data guide is also produced annually. This data guide 
outlines the data elements to be collected in more detail. Additional data requests can also be 
made on an ad hoc basis. 
Interpretability 
Information on opioid use is available in the annual report. Definitions of terms used are in 
the report to assist with interpretability. 
Relevance 
The NOPSAD collection is essential in monitoring treatment for opioid dependence 
nationally. It is one of a number of data sources that provide a picture of alcohol and other 
drug treatment services in Australia. Data from the collection can also be considered with 
information from other sources—for instance, the Alcohol and Other Drug Treatment 
Services National Minimum Data Set (AODTS NMDS) and the National Drug Strategy 
Household Survey (NDSHS)—to inform debate, policy decisions and planning processes 
that occur within the broader alcohol and other drug treatment sector. More specifically, 
pharmacotherapy data are used in states and territories to: 
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• monitor resources required for pharmacotherapy treatment, such as the number of 
prescribers and dosing point sites 
• monitor and plan services (for example, monitoring prescriber patterns and the number 
of clients) 
• develop and refine policies relating to the treatment of clients with opioid dependency 
• track the number of clients moving between the public and private sectors. 
Data are also used more broadly to fill gaps in national treatment services data. 
Accuracy 
NOPSAD data are collected on a snapshot day, usually in June each year. This method is 
appropriate for the collection and should be kept in mind when comparing the NOPSAD 
collection with other collections that use different data collection periods.  
Due to variations between states and territories in data collection methods and some 
NOPSAD elements, discrepancies noted in Table 5.1 and Table 5.2 should be kept in mind 
when interpreting these data. 
Coherence 
The NOPSAD collection is reported annually. The method of data collection and elements 
collected is consistent between years allowing for meaningful comparisons over time. 
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Appendix C: Data requests and related 
data collections 
Data requests 
The states and territories are the data custodians of information collected through the 
NOPSAD collection in their state or territory. The AIHW is the data custodian of collated 
national information obtained from each state and territory. For the AIHW, data 
custodianship means responsibility for protection, storage, analysis and dissemination of the 
data in accordance with the purpose for which the data were collected, the Australian 
Institute of Health and Welfare Act 1987 and other relevant privacy principles. 
Data requests to the AIHW can only be made for summarised aggregate tables as unit record 
file data have not been collected in previous years. Four jurisdictions piloted the reporting of 
unit record file data in 2012, and it is hoped that future collections will be based on unit 
record data. This collection is not a national minimum data set. 
Additional information about the collection is in the National Opioid Pharmacotherapy 
Statistical Annual Data (NOPSAD) 2012 collection: data guide, which is available on the AIHW 
website: <http://www.aihw.gov.au/publication-detail/?id=10737422162>. 
Related data collections 
As in previous years, a subset of the data presented in this report will be in the forthcoming 
Alcohol and other drug treatment services in Australia 2011–12 report, due for release in mid-
2013. 
If the data you require are not available from the NOPSAD collection, they may be available 
from the following sources: 
• Alcohol and Other Drug Treatment Services National Minimum Data Set  
Australian Institute of Health and Welfare 
<www.aihw.gov.au/alcohol-and-other-drugs-treatment-services-statistics/> 
• Alcohol and Other Drug Treatment Services National Minimum Data Set data cubes 
Australian Institute of Health and Welfare 
<www.aihw.gov.au/alcohol-and-other-drug-treatment-services-data-cubes/> 
• National Drug Strategy Household Survey  
Australian Institute of Health and Welfare 
<www.aihw.gov.au/national-drugs-strategy-household-surveys/> 
• Pharmaceutical Benefits Scheme 
Department of Health and Ageing 
 www.pbs.gov.au/info/browse/statistics. 
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On a snapshot day in 2012, almost 47,000 clients 
received pharmacotherapy treatment for their opioid 
dependence at 2,226 dosing points around Australia.  
As in previous years, methadone was the most common 
pharmacotherapy drug, with around two-thirds (68%) 
of clients treated with this drug. There were 1,768 
prescribers of opioid pharmacotherapy drugs, an 
increase of 14% from 2011.
